###begin article-title 0
A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers
###end article-title 0
###begin p 1
Present address: Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Viale Morgagni 50, 50134 Florence, Italy
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This licence does not permit commercial exploitation or the creation of derivative works without specific permission.
###end p 2
###begin p 3
###xml 509 510 509 510 <sup>+</sup>
###xml 583 590 583 590 <italic>in vivo</italic>
###xml 595 603 595 603 <italic>in vitro</italic>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 971 976 <span type="species:ncbi:9606">human</span>
How cell numbers are determined is not understood. Hedgehog-Gli activity is involved in precursor cell proliferation and stem cell self-renewal, and its deregulation sustains the growth of many human tumours. However, it is not known whether GLI1, the final mediator of Hh signals, controls stem cell numbers, and how its activity is restricted to curtail tumourigenesis. Here we have altered the levels of GLI1 and p53, the major tumour suppressor, in multiple systems. We show that GLI1 expression in Nestin+ neural progenitors increases precursor and clonogenic stem cell numbers in vivo and in vitro. In contrast, p53 inhibits GLI1-driven neural stem cell self-renewal, tumour growth and proliferation. Mechanistically, p53 inhibits the activity, nuclear localisation and levels of GLI1 and in turn, GLI1 represses p53, establishing an inhibitory loop. We also find that p53 regulates the phosphorylation of a novel N' truncated putative activator isoform of GLI1 in human cells. The balance of GLI1 and p53 functions, thus, determines cell numbers, and prevalence of p53 restricts GLI1-driven stem cell expansion and tumourigenesis.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 417 448 417 448 <xref ref-type="bibr" rid="b5">Dahmane and Ruiz i Altaba, 1999</xref>
###xml 458 463 458 463 <italic>et al</italic>
###xml 450 469 450 469 <xref ref-type="bibr" rid="b6">Dahmane <italic>et al</italic>, 2001</xref>
###xml 476 481 476 481 <italic>et al</italic>
###xml 471 487 471 487 <xref ref-type="bibr" rid="b28">Lien <italic>et al</italic>, 2006</xref>
###xml 554 559 554 559 <italic>et al</italic>
###xml 550 565 550 565 <xref ref-type="bibr" rid="b24">Lai <italic>et al</italic>, 2003</xref>
###xml 567 596 567 596 <xref ref-type="bibr" rid="b35">Palma and Ruiz i Altaba, 2004</xref>
###xml 604 609 604 609 <italic>et al</italic>
###xml 598 615 598 615 <xref ref-type="bibr" rid="b34">Palma <italic>et al</italic>, 2005</xref>
###xml 650 655 650 655 <italic>et al</italic>
###xml 641 661 641 661 <xref ref-type="bibr" rid="b14">Goodrich <italic>et al</italic>, 1997</xref>
###xml 682 687 682 687 <italic>et al</italic>
###xml 674 693 674 693 <xref ref-type="bibr" rid="b6">Dahmane <italic>et al</italic>, 2001</xref>
###xml 786 791 786 791 <italic>et al</italic>
###xml 778 797 778 797 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 667 672 <span type="species:ncbi:9606">human</span>
A key unresolved issue in biology is how cell numbers are determined during development, largely maintained in adulthood and deregulated in cancer. Hedgehog-Gli signalling is a key intercellular communication pathway involved in many aspects of development and cancer. During early brain development, it modulates precursor proliferation in different brain regions such as the neocortex, tectum and cerebellum (e.g., Dahmane and Ruiz i Altaba, 1999; Dahmane et al, 2001; Lien et al, 2006), while later on it regulates brain stem cell lineages (e.g., Lai et al, 2003; Palma and Ruiz i Altaba, 2004; Palma et al, 2005). It also drives rodent (Goodrich et al, 1997) and human (Dahmane et al, 2001) brain tumourigenesis and the self-renewal and survival of brain cancer stem cells (Clement et al, 2007). This dual involvement of Hh-Gli signalling in development and disease underlines its central role in controlling precursor cell numbers in the brain and other organs. It is not known, however, whether the level of GLI1 is critical to determine stem cell numbers and how GLI1 activity is restrained to prevent tumour formation.
###end p 5
###begin p 6
###xml 197 202 197 202 <italic>et al</italic>
###xml 185 208 185 208 <xref ref-type="bibr" rid="b13">Gil-Perotin <italic>et al</italic>, 2006</xref>
###xml 218 223 218 223 <italic>et al</italic>
###xml 210 229 210 229 <xref ref-type="bibr" rid="b29">Meletis <italic>et al</italic>, 2006</xref>
###xml 427 432 427 432 <italic>et al</italic>
###xml 418 438 418 438 <xref ref-type="bibr" rid="b2">Brewster <italic>et al</italic>, 2000</xref>
###xml 440 469 440 469 <xref ref-type="bibr" rid="b35">Palma and Ruiz i Altaba, 2004</xref>
###xml 478 483 478 483 <italic>et al</italic>
###xml 471 489 471 489 <xref ref-type="bibr" rid="b20">Kasper <italic>et al</italic>, 2006</xref>
###xml 497 502 497 502 <italic>et al</italic>
###xml 491 508 491 508 <xref ref-type="bibr" rid="b39">Riob&#243; <italic>et al</italic>, 2006</xref>
###xml 518 523 518 523 <italic>et al</italic>
###xml 510 529 510 529 <xref ref-type="bibr" rid="b7">Dennler <italic>et al</italic>, 2007</xref>
###xml 584 589 584 589 <italic>et al</italic>
###xml 577 595 577 595 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 735 742 735 742 <italic>in vivo</italic>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Here we have tested two hypotheses: (1) GLI1 is a central determinant of stem cell numbers; (2) p53, the major human tumour suppressor, which regulates stem cell and precursor numbers (Gil-Perotin et al, 2006; Meletis et al, 2006), does so by negatively modulating the activity of GLI1. Testing these two ideas is important, as GLI proteins can integrate patterning and proliferative inputs in addition to HH signals (Brewster et al, 2000; Palma and Ruiz i Altaba, 2004; Kasper et al, 2006; Riobo et al, 2006; Dennler et al, 2007), as well as those from oncogenic RAS-MEK/AKT (Stecca et al, 2007); and p53 suppresses whereas GLI1 promotes tumourigenesis. We report that (1) the level of GLI1 determines the number of neural stem cells in vivo, (2) GLI1 and p53 act in an inhibitory loop, (3) endogenous GLI1 isoforms exist, and (4) a novel N'Delta GLI1 isoform is subject to regulation by phosphorylation in a p53-dependent manner. Our present and previous data suggest a critical regulation of GLI1 function in stem cell lineages by oncogenes and tumour suppressors, which is off-balance in disease.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Elevation of GLI1 levels in neural progenitors results in a larger brain with expanded progenitor populations
###end title 8
###begin p 9
###xml 47 54 47 54 <italic>in vivo</italic>
###xml 120 126 120 126 <italic>Nestin</italic>
###xml 145 157 145 157 <italic>Nestin-&gt;rtTA</italic>
###xml 163 167 163 167 <italic>LacZ</italic>
###xml 176 198 176 198 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 295 303 295 303 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 305 328 305 328 <xref ref-type="supplementary-material" rid="S1">Supplementary Figures 1</xref>
###xml 330 331 330 331 <xref ref-type="supplementary-material" rid="S1">2</xref>
###xml 333 334 333 334 <xref ref-type="supplementary-material" rid="S1">3</xref>
###xml 336 337 336 337 <xref ref-type="supplementary-material" rid="S1">4</xref>
###xml 403 413 403 413 <italic>-&gt;myc-GLI1</italic>
###xml 480 484 480 484 <italic>hprt</italic>
###xml 664 685 664 685 <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>
###xml 687 709 687 709 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
To enhance Gli1 activity in stem cell lineages in vivo, we developed doxycycline (dox) inducible bigenic mice using the Nestin intron II driver (Nestin->rtTA-IRES-LacZ driver; Supplementary Figure 1), which is strongly expressed in embryonic neural progenitors but only very weakly postnatally (Figure 1; Supplementary Figures 1, 2, 3, 4 and not shown). As a responder, we made a bidirectional GFP<-tetO->myc-GLI1 transgene by random insertion (one line) or by targeting into the hprt locus (three lines). All bigenic lines showed the same phenotypes, and we focused on perinatal phenotypes of the first line resulting from sustained embryonic dox administration (Supplementary Table 1; Supplementary Figure 1).
###end p 9
###begin p 10
###xml 39 43 39 43 <sup>+dox</sup>
###xml 67 71 67 71 <sup>&#8722;dox</sup>
###xml 258 269 258 269 <xref ref-type="fig" rid="f1">Figure 1A&#8211;D</xref>
###xml 271 293 271 293 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 366 370 366 370 <sup>+dox</sup>
###xml 401 409 401 409 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 504 527 504 527 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3A</xref>
###xml 646 650 646 650 <italic>LacZ</italic>
###xml 674 678 674 678 <italic>GLI1</italic>
###xml 694 699 694 699 <italic>Ptch1</italic>
###xml 727 747 727 747 <xref ref-type="fig" rid="f1">Figure 1E&#8211;H, M and P</xref>
###xml 749 772 749 772 <xref ref-type="supplementary-material" rid="S1">Supplementary Figures 2</xref>
###xml 774 775 774 775 <xref ref-type="supplementary-material" rid="S1">3</xref>
###xml 777 778 777 778 <xref ref-type="supplementary-material" rid="S1">4</xref>
###xml 864 868 864 868 <italic>Gli1</italic>
###xml 870 901 870 901 <xref ref-type="bibr" rid="b5">Dahmane and Ruiz i Altaba, 1999</xref>
###xml 980 995 980 995 <xref ref-type="fig" rid="f1">Figure 1G and H</xref>
###xml 997 1023 997 1023 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3A, B</xref>
###xml 1140 1151 1140 1151 <xref ref-type="fig" rid="f1">Figure 1A&#8211;D</xref>
###xml 1153 1175 1153 1175 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 1268 1290 1268 1290 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 4</xref>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
Double-transgenic (DT)-treated mice (DT+dox), but not untreated (DT-dox) siblings or treated single transgenics, expressed GLI1 and GFP in precursors and displayed larger brains with hyperplasias of progenitor zones throughout from forebrain to spinal cord (Figure 1A-D; Supplementary Figure 1 and not shown). The strength of the phenotype varied within a litter. DT+dox mice with a strong phenotype (Figure 1) were embryonic lethal or died shortly after birth. Surviving animals had milder alterations (Supplementary Figure 3A). Three brain regions with strong phenotypes (cortex, thalamus and cerebellum) and the spinal cord had high levels of LacZ, GFP and Nestin and of GLI1 and endogenous Ptch1 mRNAs in progenitor cells (Figure 1E-H, M and P; Supplementary Figures 2, 3, 4). The cerebellar external germinal layer, which has the highest levels of endogenous Gli1 (Dahmane and Ruiz i Altaba, 1999), was largely unaffected, whereas the ventricular zone (VZ) was hyperplastic (Figure 1G and H; Supplementary Figure 3A, B). The tectum (colliculi) was also larger but did not show convoluted tissue as the cerebellum, thalamus or medulla (Figure 1A-D; Supplementary Figure 1). Massive and highly invasive precursor hyperplasias were also detected in the spinal cord (Supplementary Figure 4).
###end p 10
###begin p 11
###xml 11 15 11 15 <italic>GLI1</italic>
###xml 136 140 124 128 <italic>Gli1</italic>
###xml 145 150 133 138 <italic>Ptch1</italic>
###xml 152 161 140 149 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 163 185 151 173 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5</xref>
###xml 261 279 249 267 <xref ref-type="fig" rid="f1">Figure 1G, H and P</xref>
###xml 281 313 269 301 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2C, D, G, H</xref>
###xml 403 404 391 392 <sup>+</sup>
###xml 406 410 394 398 <italic>LacZ</italic>
###xml 410 411 398 399 <sup>+</sup>
###xml 413 418 401 406 <italic>Ptch1</italic>
###xml 418 419 406 407 <italic>+</italic>
###xml 418 419 406 407 <sup><italic>+</italic></sup>
###xml 429 430 417 418 <sup>+</sup>
###xml 490 505 478 493 <xref ref-type="fig" rid="f1">Figure 1I and J</xref>
###xml 507 535 495 523 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2A&#8211;E, I</xref>
###xml 563 564 547 548 <sup>&#8722;</sup>
###xml 622 631 606 615 <xref ref-type="fig" rid="f1">Figure 1I</xref>
###xml 672 681 656 665 <xref ref-type="fig" rid="f1">Figure 1J</xref>
###xml 683 709 667 693 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2B, E</xref>
###xml 732 733 716 717 <sup>+</sup>
###xml 743 752 727 736 <xref ref-type="fig" rid="f1">Figure 1K</xref>
###xml 788 793 772 777 <italic>et al</italic>
###xml 782 799 766 783 <xref ref-type="bibr" rid="b11">Farin <italic>et al</italic>, 2006</xref>
###xml 825 826 809 810 <sup>+</sup>
###xml 832 833 816 817 <sup>&#8722;</sup>
###xml 844 853 828 837 <xref ref-type="fig" rid="f1">Figure 1L</xref>
###xml 767 772 <span type="species:ncbi:9606">human</span>
Transgenic GLI1 induced approximately4-13-fold the activity of the endogenous Hh-Gli pathway as assessed by the increased expression of Gli1 and Ptch1 (Figure 2A; Supplementary Figure 5). It also boosted 2-8-fold BrdU incorporation in a region-specific manner (Figure 1G, H and P; Supplementary Figure 2C, D, G, H). In the cortex and subventricular zone of the lateral ventricle (SVZ), we found high GFP+, LacZ+, Ptch1+, myc-GLI1+ groups of cells streaming from the VZ to the pial surface (Figure 1I and J; Supplementary Figure 2A-E, I). These cells were HP1gamma-, a heterochromatin (neuronal and senescent cell) marker (Figure 1I); they expressed high levels of Nestin (Figure 1J; Supplementary Figure 2B, E), associated with CD34+ vessels (Figure 1K) similarly to human gliomas (Farin et al, 2006), and derived from Nestin+, GFAP- VZ cells (Figure 1L).
###end p 11
###begin p 12
###xml 2 6 2 6 <sup>+dox</sup>
###xml 10 11 10 11 <sup>+</sup>
###xml 88 103 88 103 <xref ref-type="fig" rid="f1">Figure 1G and H</xref>
###xml 105 124 105 124 <xref ref-type="supplementary-material" rid="S1">Supplementary 2G, H</xref>
###xml 161 184 161 184 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3C</xref>
###xml 253 257 253 257 <italic>LacZ</italic>
###xml 262 267 262 267 <italic>Ptch1</italic>
###xml 312 330 312 330 <xref ref-type="fig" rid="f1">Figure 1F, H and M</xref>
###xml 435 450 435 450 <xref ref-type="fig" rid="f1">Figure 1N and O</xref>
###xml 464 471 464 471 <italic>NeuroD1</italic>
###xml 501 524 501 524 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3D</xref>
###xml 661 671 661 667 <italic>Pdgfr&#945;</italic>
###xml 698 721 694 717 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3D</xref>
###xml 770 793 766 789 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2J</xref>
DT+dox GFP+ regions in thalamus and cerebellum showed the highest proliferative levels (Figure 1G and H; Supplementary 2G, H) with reduced (2-3-fold) apoptosis (Supplementary Figure 3C). Massive, tumour-like hyperplasias with high nuclear density, GFP, LacZ and Ptch1 expression were prominent in these regions (Figure 1F, H and M). Hyperplasias showed little differentiation as assessed, for instance, by exclusion of neuronal Prox1 (Figure 1N and O), neuroblast NeuroD1 staining in dorsal thalamus (Supplementary Figure 3D), or astrocytic GFAP expression in cerebellum (not shown). A slight increase in the expression of the oligodendrocyte progenitor marker Pdgfralpha was detected in thalamus (Supplementary Figure 3D). Unaffected regions preserved differentiation (Supplementary Figure 2J). As the strong phenotype is perinatal lethal, and we found that transgenes are silenced approximately1-2 weeks after birth, it is unclear whether such lesions could develop into frank tumours.
###end p 12
###begin title 13
GLI1 upregulates an embryonic stem cell signature in the brain and modulates different signalling pathways
###end title 13
###begin p 14
###xml 69 73 69 73 <sup>+dox</sup>
###xml 155 158 155 158 <italic>Shh</italic>
###xml 160 164 160 164 <italic>Gli1</italic>
###xml 166 169 166 169 <italic>Hip</italic>
###xml 171 176 171 176 <italic>Ptch1</italic>
###xml 178 193 178 193 <italic>Snail1 and Igf2</italic>
###xml 195 204 195 204 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 206 228 206 228 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5</xref>
###xml 290 295 290 295 <italic>Nanog</italic>
###xml 297 301 297 301 <italic>Sox2</italic>
###xml 303 307 303 307 <italic>Klf4</italic>
###xml 309 315 309 315 <italic>Nestin</italic>
###xml 317 334 317 334 <italic>Prominin1 (CD133)</italic>
###xml 339 343 339 343 <italic>Bmi1</italic>
###xml 345 354 345 354 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 412 417 412 417 <italic>et al</italic>
###xml 404 423 404 423 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 533 541 533 541 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 543 566 543 566 <xref ref-type="supplementary-material" rid="S1">Supplementary Figures 1</xref>
###xml 568 569 568 569 <xref ref-type="supplementary-material" rid="S1">2</xref>
###xml 571 572 571 572 <xref ref-type="supplementary-material" rid="S1">3</xref>
###xml 574 575 574 575 <xref ref-type="supplementary-material" rid="S1">4</xref>
###xml 657 661 657 661 <sup>+dox</sup>
###xml 703 707 703 707 <italic>Hes1</italic>
###xml 709 713 709 713 <italic>Hes5</italic>
###xml 715 721 715 721 <italic>Notch1</italic>
###xml 723 730 723 730 <italic>Jagged1</italic>
###xml 759 763 759 763 <italic>Bmp2</italic>
###xml 765 772 765 772 <italic>Bmpr-Ia</italic>
###xml 774 781 774 781 <italic>Bmpr-Ib</italic>
###xml 804 813 804 813 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 821 828 821 828 <italic>Bmpr-Ia</italic>
###xml 833 836 833 836 <italic>-Ib</italic>
###xml 904 909 904 909 <italic>et al</italic>
###xml 893 915 893 915 <xref ref-type="bibr" rid="b37">Panchision <italic>et al</italic>, 2001</xref>
###xml 970 971 970 971 <sup>+</sup>
###xml 1097 1106 1097 1106 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 389 394 <span type="species:ncbi:9606">human</span>
Gene expression analyses by qPCR of different regions of perinatal DT+dox brains showed that GLI1 induced Shh-Gli pathway components and targets including Shh, Gli1, Hip, Ptch1, Snail1 and Igf2 (Figure 2A; Supplementary Figure 5). It also upregulated a group of 'stemness' genes, including Nanog, Sox2, Klf4, Nestin, Prominin1 (CD133) and Bmi1 (Figure 2A), which is reminiscent of that of human gliomas (Clement et al, 2007). The changes in gene expression levels were greatest in the cerebellum, consistent with phenotype strength (Figure 1; Supplementary Figures 1, 2, 3, 4), although each region displayed overlapping yet context-dependent signatures. DT+dox brains also showed an increase in Notch (Hes1, Hes5, Notch1, Jagged1) and the repression of BMP (Bmp2, Bmpr-Ia, Bmpr-Ib) activity signatures (Figure 2A), with Bmpr-Ia and -Ib being key determinants for stem cell responses to BMPs (Panchision et al, 2001). Enhanced GLI1 may thus increase the number of Nestin+ stem cells reflected in the upregulation of stemness genes involving modification of Notch, BMP and other (Igf2, Nodal, Hgf; Figure 2A) signalling pathways.
###end p 14
###begin title 15
GLI1 induces an increase in the number of clonogenic neural stem cells
###end title 15
###begin p 16
###xml 55 62 55 62 <italic>in vivo</italic>
###xml 120 124 120 124 <sup>+dox</sup>
###xml 253 257 253 257 <sup>&#8722;dox</sup>
###xml 350 361 350 361 <xref ref-type="fig" rid="f2">Figure 2B&#8211;E</xref>
###xml 380 384 380 384 <sup>&#8722;dox</sup>
###xml 391 395 391 395 <sup>+dox</sup>
###xml 426 430 426 430 <sup>+dox</sup>
###xml 469 473 469 473 <sup>&#8722;dox</sup>
###xml 499 522 499 522 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 6A</xref>
###xml 593 597 593 597 <sup>+dox</sup>
###xml 604 619 604 619 <xref ref-type="fig" rid="f2">Figure 2C and D</xref>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
Given the lack of unequivocal neural stem cell markers in vivo, we tested for stem cell behaviour. Different parts of DT+dox brains showed an increase in the number of primary and secondary clonal stem cell-derived neurospheres (NS), as compared with DT-dox brains, displaying a concomitant increase in proliferation with unchanged apoptosis levels (Figure 2B-E and not shown). DT-dox and DT+dox NS remained multipotent and DT+dox produced 2-5-fold more neurons than DT-dox NS upon differentiation (Supplementary Figure 6A). Efficient NS formation from the cerebellum was only obtained from DT+dox mice (Figure 2C and D).
###end p 16
###begin p 17
###xml 89 93 89 93 <sup>+dox</sup>
###xml 121 125 121 125 <italic>GLI1</italic>
###xml 127 136 127 136 <xref ref-type="fig" rid="f2">Figure 2F</xref>
###xml 236 243 236 243 <italic>in vivo</italic>
###xml 308 313 308 313 <italic>et al</italic>
###xml 304 319 304 319 <xref ref-type="bibr" rid="b25">Lee <italic>et al</italic>, 2005</xref>
###xml 339 343 339 343 <sup>+dox</sup>
###xml 350 354 350 354 <sup>&#8722;dox</sup>
###xml 400 401 400 401 <sup>+</sup>
###xml 413 420 413 420 <italic>in vivo</italic>
###xml 456 460 444 448 <sup>+dox</sup>
###xml 468 472 456 460 <sup>&#8722;dox</sup>
###xml 474 483 462 471 <xref ref-type="fig" rid="f2">Figure 2G</xref>
###xml 498 505 486 493 <italic>in vivo</italic>
###xml 574 575 562 563 <sup>+</sup>
###xml 639 640 627 628 <sup>&#8722;</sup>
###xml 648 657 636 645 <xref ref-type="fig" rid="f2">Figure 2H</xref>
Importantly, we found a direct correlation between the number of NS formed from single DT+dox cerebella and the level of GLI1 (Figure 2F) so that higher levels of GLI1 produced more NS. To further address the role of GLI1 in stem cells in vivo, we analysed the number of stem cells expressing Prominin1 (Lee et al, 2005) by MACS sorting DT+dox and DT-dox cerebella. The number of cerebellar Prominin1+ stem cells in vivo increased approximately3-fold in DT+dox over DT-dox (Figure 2G), showing the in vivo enhancement of stem cell numbers by GLI1. As expected, the Prominin1+ fraction showed 4-6-fold increased clonogenicity over Prominin1- cells (Figure 2H).
###end p 17
###begin p 18
###xml 48 49 48 49 <sup>+</sup>
###xml 68 72 68 72 <sup>+dox</sup>
###xml 79 83 79 83 <sup>&#8722;dox</sup>
###xml 126 130 126 130 <italic>Gli1</italic>
###xml 132 135 132 135 <italic>Shh</italic>
###xml 137 142 137 142 <italic>Ptch1</italic>
###xml 144 149 144 149 <italic>Ptch2</italic>
###xml 151 156 151 156 <italic>Nanog</italic>
###xml 161 165 161 165 <italic>Hes1</italic>
###xml 219 223 219 223 <sup>+dox</sup>
###xml 236 245 236 245 <xref ref-type="fig" rid="f2">Figure 2I</xref>
###xml 247 270 247 270 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 6B</xref>
###xml 431 432 431 432 <sup>+</sup>
###xml 499 521 499 521 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5</xref>
Gene expression signatures of purified Prominin1+ stem cells from DT+dox and DT-dox E17.5 cerebella revealed an enrichment of Gli1, Shh, Ptch1, Ptch2, Nanog and Hes1 and low expression of BMP signalling components in DT+dox stem cells (Figure 2I; Supplementary Figure 6B), showing an action of GLI1 in stem cells. Gene expression analyses of whole E17.5 NS further supported the findings with dissected brain and purified Prominin1+ stem cells, although a number of genes showed variant expression (Supplementary Figure 5), probably reflecting different cellular compositions.
###end p 18
###begin title 19
Cooperation of GLI1 and p53 knock-down on neural stem cell self-renewal and tumour growth
###end title 19
###begin p 20
###xml 22 25 22 25 <italic>p21</italic>
###xml 30 34 30 34 <italic>Puma</italic>
###xml 65 66 65 66 <sup>+</sup>
###xml 83 87 83 87 <sup>+dox</sup>
###xml 99 108 99 108 <xref ref-type="fig" rid="f2">Figure 2I</xref>
###xml 208 213 208 213 <italic>et al</italic>
###xml 196 219 196 219 <xref ref-type="bibr" rid="b13">Gil-Perotin <italic>et al</italic>, 2006</xref>
###xml 229 234 229 234 <italic>et al</italic>
###xml 221 240 221 240 <xref ref-type="bibr" rid="b29">Meletis <italic>et al</italic>, 2006</xref>
###xml 280 284 280 284 <sup>+dox</sup>
###xml 341 343 341 343 <italic>DT</italic>
###xml 343 347 343 347 <italic>+dox</italic>
###xml 343 347 343 347 <sup><italic>+dox</italic></sup>
###xml 348 351 348 351 <italic>p53</italic>
###xml 351 354 351 354 <sup>&#8722;/&#8722;</sup>
###xml 30 34 <span type="species:ncbi:9696">Puma</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
The downregulation of p21 and Puma, two p53 targets, in Prominin1+ stem cells of DT+dox cerebella (Figure 2I) is consistent with the finding that p53 negatively controls neural stem cell numbers (Gil-Perotin et al, 2006; Meletis et al, 2006). Because the perinatal lethality of DT+dox mice with strong phenotypes prevented us from analysing DT+dox;p53-/- mice for the possible development of frank tumours and further expansion of stem cell pools, we first tested for the role of p53 on GLI1-induced NS self-renewal.
###end p 20
###begin p 21
###xml 30 34 30 34 <sup>&#8722;dox</sup>
###xml 41 45 41 45 <sup>+dox</sup>
###xml 336 345 336 345 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 418 433 418 433 <xref ref-type="fig" rid="f3">Figure 3B and C</xref>
###xml 508 512 508 512 <italic>GLI1</italic>
###xml 516 523 516 523 <italic>shPtch1</italic>
###xml 703 714 703 714 <xref ref-type="fig" rid="f3">Figure 3D&#8211;F</xref>
E17.5 cortical and thalamic DT-dox and DT+dox NS, or wt NS transduced with control or GLI1-expressing lentivectors were further transduced with a control or an shRNA specific for p53 (shp53). Enhanced GLI1 or knock-down (kd) of p53 increased the number of clones as expected, but importantly, their simultaneous action was synergistic (Figure 3A). They also increased proliferation and decreased apoptosis additively (Figure 3B and C). Wt postnatal SVZ NS transduced with lentivectors expressing full-length GLI1 or shPtch1 (to endogenously enhance the Shh-Gli1 pathway) alone and in combination with shp53 yielded similar synergism in clonogenicity and additive results in proliferation and apoptosis (Figure 3D-F). p53 therefore antagonises GLI1 in the control of neural stem cell self-renewal in NS of different brain regions.
###end p 21
###begin p 22
###xml 269 273 269 273 <sup>+dox</sup>
###xml 313 320 313 320 <italic>in vivo</italic>
###xml 484 489 484 489 <italic>et al</italic>
###xml 481 495 481 495 <xref ref-type="bibr" rid="b27">Li <italic>et al</italic>, 2008</xref>
###xml 740 755 740 755 <xref ref-type="fig" rid="f3">Figure 3G and H</xref>
###xml 914 929 914 929 <xref ref-type="fig" rid="f3">Figure 3G and H</xref>
###xml 1008 1012 1008 1012 <italic>Ptc1</italic>
###xml 1012 1015 1012 1015 <sup>+/&#8722;</sup>
###xml 1016 1019 1016 1019 <italic>p53</italic>
###xml 1019 1022 1019 1022 <sup>&#8722;/&#8722;</sup>
###xml 1045 1049 1045 1049 <italic>Ptc1</italic>
###xml 1071 1076 1071 1076 <italic>et al</italic>
###xml 1063 1082 1063 1082 <xref ref-type="bibr" rid="b52">Wetmore <italic>et al</italic>, 2001</xref>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
Following these findings, we tested whether enhanced GLI1 cooperates with p53 kd in tumour growth. As all patient-derived glioblastoma stem cell cultures that efficiently grew in our hands were p53 mutant (M Vucikevic and ARA, personal communication), and as NS from DT+dox mice extinguished transgene expression in vivo after transplantation (not shown), we used human U87 glioblastoma (p53 wt) cells. These cells show the least number of genomic changes among glioma cell lines (Li et al, 2008). Cells transduced with lentivectors expressing GLI1 or GLI1 plus shp53 were grafted intracranially and tumours removed when the mice showed signs of neurological disease. Enhanced GLI1 expression induced an acceleration of tumour development (Figure 3G and H) and an increase in tumour weight as compared with controls. p53 kd alone did not accelerate tumour development, but it synergised with enhanced GLI1 levels (Figure 3G and H). These results are consistent with the acceleration of cerebellar tumours in Ptc1+/-;p53-/- mice as compared with Ptc1+/- siblings (Wetmore et al, 2001), although the bases of such acceleration is unknown.
###end p 22
###begin title 23
Balancing SHH-GLI and p53 activities in the control of tumour cell numbers
###end title 23
###begin p 24
###xml 70 75 70 75 <italic>et al</italic>
###xml 62 81 62 81 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 90 95 90 95 <italic>et al</italic>
###xml 83 101 83 101 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 164 169 164 169 <italic>et al</italic>
###xml 156 175 156 175 <xref ref-type="bibr" rid="b43">Sanchez <italic>et al</italic>, 2004</xref>
###xml 184 189 184 189 <italic>et al</italic>
###xml 177 195 177 195 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 254 265 254 265 <xref ref-type="fig" rid="f4">Figure 4A&#8211;C</xref>
###xml 326 341 326 341 <xref ref-type="fig" rid="f4">Figure 4A and B</xref>
###xml 510 525 510 525 <xref ref-type="fig" rid="f4">Figure 4A and B</xref>
###xml 617 626 617 626 <xref ref-type="fig" rid="f4">Figure 4C</xref>
As expected, kd of HH-GLI signalling with a validated shSMOH (Clement et al, 2007; Stecca et al, 2007) or with validated 21-nt siRNAs against GLI1 (siGLI1; Sanchez et al, 2004; Stecca et al, 2007) decreased U87 cell proliferation and enhanced apoptosis (Figure 4A-C). In contrast, p53 kd increased proliferation of U87 cells (Figure 4A and B). Interestingly, epistatic analyses revealed that shp53-enhanced proliferation was blocked by both shSMOH and siGLI1 but not by control lentivectors or control siRNAs (Figure 4A and B) on the one hand, whereas on the other, cell death induced by shSMOH was blocked by shp53 (Figure 4C), suggesting mutual requirement.
###end p 24
###begin p 25
###xml 244 253 244 253 <xref ref-type="fig" rid="f4">Figure 4D</xref>
###xml 400 409 400 409 <xref ref-type="fig" rid="f4">Figure 4E</xref>
###xml 531 540 531 540 <xref ref-type="fig" rid="f4">Figure 4E</xref>
###xml 689 694 689 694 <italic>et al</italic>
###xml 679 700 679 700 <xref ref-type="bibr" rid="b15">Gorgoulis <italic>et al</italic>, 2005</xref>
###xml 873 874 873 874 <sup>+</sup>
###xml 886 890 886 890 <sup>+dox</sup>
###xml 937 963 937 963 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 7A, B</xref>
Consistent with this idea, restoration of p53 function in p53-mutant brain tumour cells (U251 glioma and Daoy medulloblastoma) reduced, and enhancement of GLI1 levels increased, their proliferation, but these effects were mutually compensated (Figure 4D). Similarly, oxaliplatin treatment of U87 cells increased endogenous p53 levels through the DNA damage response and decreased cell proliferation (Figure 4E), but this proliferative defect and the level of induced phospho-p53 were attenuated in cells with enhanced GLI1 levels (Figure 4E), further suggesting a balance of levels and activities. Enhanced GLI1 levels, however, also induced hallmarks of DNA replication stress (Gorgoulis et al, 2005) that are known to lead to enhanced p53 function in different scenarios: increasing the number of 53BP1 protein foci in 293T cells and increasing the number of phospho-Chk2+ cells in DT+dox hyperplastic thalamic and cerebellar regions (Supplementary Figure 7A, B). Together, these data suggest an endogenous antagonistic relationship between p53 and GLI1 but also the possible induction of p53 function by GLI1 through the DNA replication stress response.
###end p 25
###begin title 26
Epidermal hyperplasias induced by interference with p53 function require endogenous Gli1
###end title 26
###begin p 27
###xml 115 130 115 130 <xref ref-type="fig" rid="f4">Figure 4A and B</xref>
###xml 258 265 258 265 <italic>in vivo</italic>
###xml 410 413 410 413 <sup>280</sup>
###xml 522 527 522 527 <italic>et al</italic>
###xml 510 533 510 533 <xref ref-type="bibr" rid="b51">Wallingford <italic>et al</italic>, 1997</xref>
###xml 666 667 666 667 <italic>n</italic>
###xml 697 708 697 708 <xref ref-type="fig" rid="f4">Figure 4F&#8211;H</xref>
###xml 771 775 771 775 <italic>Gli1</italic>
###xml 785 790 785 790 <italic>et al</italic>
###xml 777 796 777 796 <xref ref-type="bibr" rid="b4">Dahmane <italic>et al</italic>, 1997</xref>
###xml 798 802 798 802 <xref ref-type="bibr" rid="b6">2001</xref>
###xml 811 816 811 816 <italic>et al</italic>
###xml 804 822 804 822 <xref ref-type="bibr" rid="b31">Nguyen <italic>et al</italic>, 2005</xref>
###xml 894 895 882 883 <italic>n</italic>
###xml 950 954 938 942 <italic>Gli1</italic>
###xml 959 960 947 948 <italic>n</italic>
###xml 992 993 980 981 <italic>n</italic>
###xml 1050 1054 1038 1042 <italic>GLI1</italic>
###xml 1063 1074 1051 1062 <xref ref-type="fig" rid="f4">Figure 4F&#8211;H</xref>
###xml 1084 1089 1072 1077 <italic>et al</italic>
###xml 1076 1095 1064 1083 <xref ref-type="bibr" rid="b4">Dahmane <italic>et al</italic>, 1997</xref>
###xml 1097 1101 1085 1089 <xref ref-type="bibr" rid="b6">2001</xref>
###xml 1110 1115 1098 1103 <italic>et al</italic>
###xml 1103 1121 1091 1109 <xref ref-type="bibr" rid="b31">Nguyen <italic>et al</italic>, 2005</xref>
###xml 1147 1151 1135 1139 <italic>Gli1</italic>
###xml 1337 1352 1325 1340 <xref ref-type="fig" rid="f4">Figure 4G and H</xref>
###xml 1044 1049 <span type="species:ncbi:9606">human</span>
The blockade of shp53-mediated increased cell proliferation by interference with endogenous SMOH or GLI1 function (Figure 4A and B) suggested that interference with p53 frees endogenous GLI1 from negative regulation, leading to cell overproliferation. As an in vivo assay to analyse this idea, we tested for the role of Gli1 in tumours induced by blockade of p53. Frog embryos expressing dominant negative (Thr280) p53 (dnp53), which inhibits endogenous p53 function, develop epidermal tumours (hyperplasias) (Wallingford et al, 1997). Co-injection of a control antisense morpholino oligonucleotide (MO) along with dnp53 did not modify its tumour-inducing activity (n=18/19 tadpoles with tumours; Figure 4F-H). In contrast, coinjection with a proven MO specific for frog Gli1 (Dahmane et al, 1997, 2001; Nguyen et al, 2005) reduced the development of dnp53-induced tumours by approximately40% (n=21/37). As a control for MO specificity, injection of Gli1 MO (n=6/24), but not the control MO (n=27/27), reduced tumour development by co-injected human GLI1 by 66% (Figure 4F-H; Dahmane et al, 1997, 2001; Nguyen et al, 2005). Blockade of endogenous Gli1 changed the distribution of the descendants of the injected blastomeres from clumped in tumours to evenly in the epidermis, appropriate for the normal fate of the injected blastomeres (Figure 4G and H). Enhanced GLI1 function (through injection) therefore bypasses proliferative restrictions imposed by p53, and blockade of endogenous p53 unleashes the proliferative activity of endogenous Gli1.
###end p 27
###begin title 28
p53 negatively regulates the activity, nuclear localisation and levels of GLI1
###end title 28
###begin p 29
###xml 149 171 149 171 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 8</xref>
###xml 236 245 236 245 <italic>Prominin1</italic>
###xml 247 251 247 251 <italic>Bmi1</italic>
###xml 256 261 256 261 <italic>Nanog</italic>
###xml 274 277 274 277 <italic>p16</italic>
###xml 279 283 279 283 <italic>Gli1</italic>
###xml 285 289 285 289 <italic>Hes1</italic>
###xml 291 295 291 295 <italic>Hes5</italic>
###xml 364 367 364 367 <italic>p21</italic>
Gene expression analyses of NS expressing both GLI1 and shp53 revealed context-specific differences in the effect of p53 kd on GLI1-regulated genes (Supplementary Figure 8), for instance, increasing the expression of the stemness genes Prominin1, Bmi1 and Nanog, as well as p16, Gli1, Hes1, Hes5 and other Notch components in different regions, whereas decreasing p21 in cortex and cerebellum, all as compared with NS expressing GLI1.
###end p 29
###begin p 30
###xml 306 321 306 321 <xref ref-type="fig" rid="f5">Figure 5A and B</xref>
###xml 323 346 323 346 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9A</xref>
###xml 458 467 454 463 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 548 557 540 549 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 559 582 551 574 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9A</xref>
###xml 830 839 822 831 <xref ref-type="fig" rid="f5">Figure 5C</xref>
###xml 841 864 833 856 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9B</xref>
###xml 900 904 892 896 <italic>GLI1</italic>
###xml 1150 1169 1138 1157 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 1171 1186 1159 1174 <xref ref-type="fig" rid="f5">Figure 5D and E</xref>
###xml 1338 1343 1326 1331 <italic>et al</italic>
###xml 1327 1349 1315 1337 <xref ref-type="bibr" rid="b17">Huntzicker <italic>et al</italic>, 2006</xref>
###xml 236 241 <span type="species:ncbi:10090">mouse</span>
###xml 277 282 <span type="species:ncbi:9606">human</span>
To elucidate how p53 alters the genetic program induced by GLI1, we first asked whether p53 affects GLI1-dependent transcription in GLI-dependent luciferase reporter assays. shp53 increased 2-3-fold the activity of GLI1 in wt postnatal mouse SVZ NS, and this was reproduced in human U87 and in 293T cells (Figure 5A and B; Supplementary Figure 9A). dnp53 behaved similarly and p53 kd also augmented the diminished activity of N'Delta forms of GLI1 and GLI2 (Figure 5A). shp53 did not endow GLI3 or its C'Delta repressor form (GLI3R) with activity (Figure 5A; Supplementary Figure 9A), suggesting that it does not act by inhibiting repressor function. Conversely, restoring p53 activity in U251 and Daoy cells (both p53 mutant) decreased GLI1 reporter activity and the levels of exogenous GLI1 in a concentration-dependent manner (Figure 5C; Supplementary Figure 9B). p53 did not affect the levels of GLI1 mRNA in co-transfected cells (not shown). Enhanced transcriptional activity by shp53 was correlated with two-fold enhanced nuclear localisation of GLI1, of N'Delta forms of GLI1 and GLI2 but not of GLI3, GLI3R or of a nuclear targeted NLS-Gli1 (Ruiz i Altaba, 1999; Figure 5D and E). p53 thus appears to promote the localisation of GLI1, and possibly of GLI2, in the cytoplasm, where it can be degraded by the proteasome (Huntzicker et al, 2006).
###end p 30
###begin p 31
###xml 123 127 123 127 <sup>+dox</sup>
###xml 281 297 277 281 <sup>&#8764;420</sup>
###xml 451 460 433 442 <xref ref-type="fig" rid="f5">Figure 5F</xref>
###xml 616 623 594 601 <sup>803&#8722;818</sup>
###xml 766 775 732 741 <xref ref-type="fig" rid="f5">Figure 5G</xref>
###xml 807 823 769 773 <sup>&#8764;420</sup>
###xml 855 864 805 814 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 885 892 831 838 <sup>803&#8722;818</sup>
###xml 968 973 902 907 <italic>Ptch1</italic>
###xml 973 976 907 910 <sup>+/&#8722;</sup>
###xml 977 980 911 914 <italic>p53</italic>
###xml 980 983 914 917 <sup>&#8722;/&#8722;</sup>
###xml 1006 1015 940 949 <xref ref-type="fig" rid="f5">Figure 5H</xref>
###xml 1087 1088 1021 1022 <sup>+</sup>
###xml 1145 1149 1079 1083 <italic>GLI1</italic>
###xml 1157 1188 1091 1122 <xref ref-type="bibr" rid="b5">Dahmane and Ruiz i Altaba, 1999</xref>
###xml 1198 1203 1132 1137 <italic>et al</italic>
###xml 1190 1209 1124 1143 <xref ref-type="bibr" rid="b6">Dahmane <italic>et al</italic>, 2001</xref>
###xml 1438 1447 1372 1381 <xref ref-type="fig" rid="f5">Figure 5H</xref>
###xml 549 554 <span type="species:ncbi:10090">mouse</span>
###xml 671 676 <span type="species:ncbi:10090">mouse</span>
###xml 843 848 <span type="species:ncbi:10090">mouse</span>
To test whether p53 generally inhibits GLI1 levels, we analysed GLI1 protein in different contexts. E17.5 thalamic NS of DT+dox brains were transduced with control or shp53 lentivectors and kept in the presence of dox. Western blots with a commercial anti-GLI1 antibody (alpha-GLI1approximately420; Cell Signalling) showed that p53 kd induced a 30% increase in full-length GLI1 (>160 KD) and a three-fold increase of a shorter form running +/-130 KD (Figure 5F), quantified by densitometry. Similarly, analysis of postnatal wt SVZ NS for endogenous mouse Gli1 with an anti-GLI1 antibody to the C-terminus (alpha-GLI1803-818; GeneTex) showed a 40% increase in full-length mouse Gli1 (>160 KD) and a 2.3-fold increase in a shorter form running at approximately115 KD (Figure 5G). As control, and as alpha-GLI1approximately420 does not recognise mouse Gli1 (Figure 6C), we used alpha-GLI1803-818 to probe extracts of P10 wt cerebellum, adult (approximately4 mo) Cb and a Ptch1+/-;p53-/- medulloblastoma (MB) (Figure 5H). As expected from the transient perinatal expansion of cerebellar GLI1+ granule neuron progenitors and the strong expression of GLI1 in MB (Dahmane and Ruiz i Altaba, 1999; Dahmane et al, 2001), the full-length and the shorted 115 KD form were clearly detected at P10 and were nearly undetectable in adult cerebellum, whereas the full-length form was 14-fold and the 115 KD form 6.5-fold more abundant in MB than at P10 (Figure 5H).
###end p 31
###begin title 32
GLI1 represses p53
###end title 32
###begin p 33
###xml 48 57 48 57 <xref ref-type="fig" rid="f4">Figure 4D</xref>
###xml 101 110 101 110 <xref ref-type="fig" rid="f4">Figure 4B</xref>
###xml 478 487 478 487 <xref ref-type="fig" rid="f6">Figure 6E</xref>
The mutual compensatory effect of GLI1 and p53 (Figure 4D) and the dominance of GLI1 kd over p53 kd (Figure 4B) raised the possibility that in addition to the negative regulation of GLI1 by p53, p53 itself could be under GLI1 regulation. Analyses of p53 in GLI1 kd cells (see below) revealed that endogenous p53 is under the control of endogenous GLI1 as assessed by the levels of total p53 and of active phospho-serine15 p53 (p53-P) in cells lipofected with siGLI1 versus siC (Figure 6E). The kd of endogenous GLI1 function increased p53 approximately5-fold and phospho-serine15 p53 approximately2-fold. This indicates that in addition to the inhibition of GLI1 by p53 described earlier, endogenous GLI1 regulates the levels of endogenous p53, suggesting a negative regulatory loop.
###end p 33
###begin p 34
###xml 48 56 48 56 <italic>in vitro</italic>
###xml 111 116 111 116 <italic>et al</italic>
###xml 107 122 107 122 <xref ref-type="bibr" rid="b1">Abe <italic>et al</italic>, 2008</xref>
###xml 198 202 198 202 <sup>+dox</sup>
###xml 212 216 212 216 <sup>&#8722;dox</sup>
###xml 225 234 225 234 <xref ref-type="fig" rid="f6">Figure 6F</xref>
###xml 287 294 287 294 <italic>in vivo</italic>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
Enhanced GLI1 levels can inhibit p53 regulation in vitro through the activation of the p53 inhibitor Hdm2 (Abe et al, 2008). We find that Mdm2, the mouse homologue of Hdm2, is greatly enhanced in DT+dox versus DT-dox brains (Figure 6F), extending this possible mechanism of action to an in vivo context.
###end p 34
###begin p 35
###xml 165 174 165 174 <xref ref-type="fig" rid="f6">Figure 6G</xref>
###xml 184 189 184 189 <italic>et al</italic>
###xml 176 195 176 195 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 258 267 258 267 <xref ref-type="fig" rid="f6">Figure 6G</xref>
###xml 287 290 287 290 <italic>p53</italic>
###xml 484 493 484 493 <xref ref-type="fig" rid="f6">Figure 6G</xref>
###xml 706 711 706 711 <italic>et al</italic>
###xml 701 717 701 717 <xref ref-type="bibr" rid="b21">Kato <italic>et al</italic>, 2003</xref>
###xml 841 844 841 844 <sup>130</sup>
The inhibitory loop between GLI1 and p53 is consistent with the inversely reciprocal levels of GLI1 and p53 observed in two primary glioblastoma stem cell cultures (Figure 6G; Clement et al, 2007). The level of GLI1 correlated with their proliferation rate (Figure 6G). GBM12 harbours a p53 gene with a frameshift mutation corresponding to aa 209 (M Vukicevic and ARA, unpublished) and predicted to encode an unstable protein as no p53 or phospho-serine15 p53 proteins were detected (Figure 6G). GBM13 expresses full-length p53 with an R->H substitution at aa 158 within the DNA-binding domain (M Vukicevic and ARA, unpublished) predicted to yield a protein with compromised transcriptional activity (Kato et al, 2003). Whereas full-length GLI1 protein was barely detectable (not shown), GMB12, which has no p53, showed higher levels of GLI1130 (see below) than GBM13, which expresses p53 with reduced activity.
###end p 35
###begin title 36
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human GLI1 isoforms
###end title 36
###begin p 37
###xml 41 52 41 52 <xref ref-type="fig" rid="f5">Figure 5F&#8211;H</xref>
###xml 260 269 260 269 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 331 333 331 333 <sup>FL</sup>
###xml 423 426 411 414 <sup>110</sup>
###xml 547 566 527 546 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 607 614 587 594 <italic>de novo</italic>
###xml 667 670 647 650 <sup>100</sup>
###xml 680 682 660 662 <sup>FL</sup>
###xml 684 693 664 673 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 903 926 883 906 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9C</xref>
###xml 179 184 <span type="species:ncbi:9606">human</span>
Given the existence of isoforms of GLI1 (Figure 5F-H), reminiscent of those of other Gli proteins, we investigated the possibility that p53 affects their formation or function in human cells. Transfection of U251 glioma cells with full-length myc-tagged GLI1 (Figure 6A, left) revealed the full-length form running at >160 KD (GLI1FL) plus one predominant smaller N-terminal tagged form running at approximately110 KD (GLI1110) after probing the western with alpha-N' myc tag antibodies. This form has been proposed to act as a C'Delta repressor (Ruiz i Altaba, 1999). Treatment with cycloheximide to block de novo protein synthesis showed increased stability of GLI1100 over GLI1FL (Figure 6A, left). The production of distinct GLI1 isoforms could be limiting in different cells or context dependent as GLI1 transfected in U87 cells yielded the full-length protein but only traces of smaller products (Supplementary Figure 9C). This variance also suggests that the stable products seen in U251 are not non-specific, ubiquitous degradation products.
###end p 37
###begin p 38
###xml 99 106 95 102 <sup>412&#8722;427</sup>
###xml 223 228 219 224 <italic>et al</italic>
###xml 215 234 211 230 <xref ref-type="bibr" rid="b4">Dahmane <italic>et al</italic>, 1997</xref>
###xml 426 435 406 415 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 635 638 615 618 <sup>130</sup>
###xml 658 661 638 641 <sup>100</sup>
###xml 722 724 702 704 <sup>FL</sup>
###xml 750 759 730 739 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 920 922 880 882 <sup>FL</sup>
###xml 935 938 895 898 <sup>130</sup>
###xml 960 962 920 922 <sup>FL</sup>
###xml 971 974 931 934 <sup>100</sup>
###xml 976 985 936 945 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 997 1000 957 960 <sup>100</sup>
###xml 1005 1008 965 968 <sup>130</sup>
###xml 1014 1016 973 975 <sup>FL</sup>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
To directly monitor GLI1 isoforms, we developed an affinity-purified, specific antibody (alpha-GLI1412-427) against a domain immediately C-terminal to the zinc fingers of human GLI1 that we had previously targeted (Dahmane et al, 1997). Reprobing the anti-myc tag westerns in human U251 cells with alpha-GLI1 revealed the same full-length and 110 KD isoforms plus a novel approximately130 KD form at similar exogenous levels (Figure 6A, right). This form lacks the myc tags and thus the N-terminus. Endogenous GLI1 was expressed at much lower levels (see below). Treatment with cycloheximide showed differential isoform stability: GLI1130 peaked at 1 h, GLI1100 was largely stable with a 1.6-fold increase at 4 h, and GLI1FL decayed 2.4-fold at 4 h (Figure 6A, right). As the 130 KD N'Delta species cannot give rise to the approximately100 KD C'Delta form, this suggests a precursor-product relationship between the GLI1FL and the GLI1130 form and between GLI1FL and GLI1100 (Figure 6B), with GLI1100>GLI1130>>GLI1FL stabilities, arguing against the first two being non-specific degradation products.
###end p 38
###begin p 39
###xml 124 140 120 124 <sup>&#8764;420</sup>
###xml 182 189 162 169 <sup>412&#8722;427</sup>
###xml 228 235 204 211 <sup>803&#8722;818</sup>
###xml 259 263 235 239 <sup>+dox</sup>
###xml 270 274 246 250 <sup>&#8722;dox</sup>
###xml 319 321 295 297 <sup>FL</sup>
###xml 327 330 303 306 <sup>130</sup>
###xml 339 342 315 318 <sup>100</sup>
###xml 388 395 360 367 <sup>412&#8722;427</sup>
###xml 410 426 378 382 <sup>&#8764;420</sup>
###xml 452 461 408 417 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 474 481 426 433 <sup>412&#8722;427</sup>
###xml 552 561 504 513 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 587 594 535 542 <sup>803&#8722;818</sup>
###xml 609 611 557 559 <sup>FL</sup>
###xml 620 623 568 571 <sup>130</sup>
###xml 636 639 584 587 <sup>100</sup>
###xml 641 650 589 598 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 723 726 671 674 <sup>100</sup>
###xml 756 759 704 707 <sup>130</sup>
###xml 761 770 709 718 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 840 847 784 791 <sup>805&#8722;820</sup>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
To further characterise the structure of the isoforms, we used two commercial polyclonal antibodies against GLI1: alpha-GLI1approximately420 made to the same region as our alpha-GLI1412-427 and the C-terminal antibody alpha-GLI1803-818. Western blots of P0 DT+dox and DT-dox brain extracts revealed the presence of GLI1FL, GLI1130 and GLI1100 only after induction with dox with alpha-GLI1412-427 and alpha-GLI1approximately420, confirming specificity (Figure 6C). alpha-GLI1412-427 also picked up a non-specific band in mouse brain extracts (asterisk, Figure 6C). In contrast, alpha-GLI1803-818 picked up GLI1FL and GLI1130 but not GLI1100 (Figure 6C) (and minor background bands), consistent with the C' truncation of GLI1100 and the N' truncation of GLI1130 (Figure 6B). Probing with a different polyclonal C-terminal antibody (alpha-GLI1805-820; Chemicon) made to the same region gave the same results (not shown).
###end p 39
###begin p 40
###xml 154 159 154 159 <italic>et al</italic>
###xml 146 165 146 165 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 267 274 259 266 <sup>412&#8722;427</sup>
###xml 328 337 320 329 <xref ref-type="fig" rid="f6">Figure 6D</xref>
###xml 339 362 331 354 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9D</xref>
###xml 395 410 387 402 <xref ref-type="fig" rid="f6">Figure 6A and C</xref>
###xml 579 586 563 570 <sup>412&#8722;427</sup>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 609 614 <span type="species:ncbi:9606">human</span>
To analyse whether endogenous human GLI1 isoforms exist, we probed western blots of U87 cells that are known to harbour an active HH-GLI pathway (Clement et al, 2007) with our own and seven commercial alpha-GLI1 antibodies (see Materials and methods). Only alpha-GLI1412-427 yielded the expected pattern of endogenous isoforms (Figure 6D; Supplementary Figure 9D and not shown) seen previously (Figure 6A and C). The other antibodies revealed various non-consistent patterns (not shown). Thus, whereas many alpha-GLI1 antibodies recognise enhanced levels of GLI1, only alpha-GLI1412-427 recognises endogenous human GLI1.
###end p 40
###begin p 41
###xml 77 82 77 82 <italic>et al</italic>
###xml 69 88 69 88 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 144 151 140 147 <sup>412&#8722;427</sup>
###xml 183 186 179 182 <sup>130</sup>
###xml 191 194 187 190 <sup>100</sup>
###xml 199 201 195 197 <sup>FL</sup>
###xml 214 223 210 219 <xref ref-type="fig" rid="f6">Figure 6D</xref>
###xml 230 233 226 229 <sup>130</sup>
###xml 312 317 308 313 <italic>et al</italic>
###xml 305 323 301 319 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 373 382 369 378 <xref ref-type="fig" rid="f6">Figure 6D</xref>
###xml 406 408 402 404 <sup>FL</sup>
###xml 417 420 413 416 <sup>100</sup>
###xml 522 537 518 533 <xref ref-type="fig" rid="f6">Figure 6A and C</xref>
###xml 715 741 699 725 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9E, F</xref>
###xml 14 21 <span type="species:ncbi:9606">patient</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 396 401 <span type="species:ncbi:9606">human</span>
###xml 637 642 <span type="species:ncbi:9606">human</span>
Analysis of a patient-derived glioblastoma stem cell culture (GMB12; Clement et al, 2007) and a panel of human tumour cell lines with alpha-GLI1412-427 revealed all isoforms with GLI1130>GLI1100>GLI1FL abundances (Figure 6D). GLI1130 was most prevalent in metastatic melanomas (which harbour active GLI1; Stecca et al, 2007), and it was consistently detected as a doublet (Figure 6D). Endogenous human GLI1FL and GLI1100 do not have N' myc tags and are therefore slightly smaller than their tagged exogenous counterparts (Figure 6A and C). Commercial westerns further confirmed the presence of a GLI1 approximately130 KD form in various human tissues and tumours with a possible tumour-specific alteration in GLI1 (Supplementary Figure 9E, F).
###end p 41
###begin p 42
###xml 63 70 59 66 <sup>412&#8722;427</sup>
###xml 168 172 164 168 <italic>GLI1</italic>
###xml 195 200 191 196 <italic>et al</italic>
###xml 187 206 183 202 <xref ref-type="bibr" rid="b43">Sanchez <italic>et al</italic>, 2004</xref>
###xml 216 221 212 217 <italic>et al</italic>
###xml 208 227 204 223 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 236 241 232 237 <italic>et al</italic>
###xml 229 247 225 243 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 300 302 296 298 <sup>FL</sup>
###xml 317 320 313 316 <sup>130</sup>
###xml 337 340 333 336 <sup>100</sup>
###xml 387 396 383 392 <xref ref-type="fig" rid="f6">Figure 6E</xref>
To verify the identity of the isoforms recognised by alpha-GLI1412-427, we used RNAi to kd endogenous GLI1. Lipofection of a specific siRNA previously proven to target GLI1 mRNA (siGLI1; Sanchez et al, 2004; Clement et al, 2007; Stecca et al, 2007) but not of a control siRNA (siC), knocked-down GLI1FL two-fold, GLI1130 13-fold and GLI1100 4.4-fold. The levels of HSP90 were unaltered (Figure 6E).
###end p 42
###begin title 43
Constructs that approximate the GLI1 N' and C' isoforms have divergent functions
###end title 43
###begin p 44
###xml 139 142 135 138 <sup>130</sup>
###xml 159 162 151 154 <sup>100</sup>
###xml 193 212 177 196 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 310 319 294 303 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 326 331 310 315 <italic>et al</italic>
###xml 321 337 305 321 <xref ref-type="bibr" rid="b53">Yoon <italic>et al</italic>, 1998</xref>
###xml 448 467 432 451 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 470 479 454 463 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 588 590 568 570 <sup>FL</sup>
###xml 737 742 717 722 <italic>et al</italic>
###xml 732 748 712 728 <xref ref-type="bibr" rid="b53">Yoon <italic>et al</italic>, 1998</xref>
###xml 757 762 737 742 <italic>et al</italic>
###xml 750 768 730 748 <xref ref-type="bibr" rid="b45">Sasaki <italic>et al</italic>, 1999</xref>
To address the possible functional significance of GLI1 isoforms, we analysed the activity of GLI1 constructs that approximate N'Delta GLI1130 and C'Delta GLI1100 (GLI1N'Delta and GLI1C'Delta; Ruiz i Altaba, 1999). Consistent with the presence of the transcriptional activation domain close to the C-terminus (Figure 6B; Yoon et al, 1998), these constructs behaved as weak activators or repressors, respectively, in GLI1-dependent reporter assays (Ruiz i Altaba, 1999) (Figure 5A). The strength of GLI1N'Delta activator was context dependent, as its activity was 1.2-fold weaker than GLI1FL in melanoma SkMel2 cells but 3.4-fold stronger in prostate cancer LNCaP cells (not shown), and similarly or more active in other cell types (Yoon et al, 1998; Sasaki et al, 1999).
###end p 44
###begin title 45
###xml 49 52 49 52 <sup>130</sup>
p53 and HH signalling regulate the status of GLI1130
###end title 45
###begin p 46
###xml 131 139 131 139 <italic>in vitro</italic>
###xml 208 215 199 206 <sup>412&#8722;427</sup>
###xml 269 272 260 263 <sup>130</sup>
###xml 299 314 290 305 <xref ref-type="fig" rid="f7">Figure 7A and D</xref>
###xml 372 375 363 366 <sup>130</sup>
###xml 381 385 372 376 <sup>130P</sup>
###xml 392 395 383 386 <sup>100</sup>
###xml 440 449 431 440 <xref ref-type="fig" rid="f7">Figure 7A</xref>
###xml 464 466 455 457 <sup>FL</sup>
###xml 488 497 479 488 <xref ref-type="fig" rid="f7">Figure 7A</xref>
###xml 664 666 655 657 <sup>FL</sup>
###xml 799 822 790 813 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9G</xref>
###xml 829 831 820 822 <sup>FL</sup>
###xml 840 844 831 835 <sup>130P</sup>
###xml 861 864 852 855 <sup>130</sup>
###xml 955 978 946 969 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9H</xref>
The existence of GLI1 isoforms raised the possibility that p53 could alter their genesis or levels. Treatment of U87 cell extracts in vitro with lambda phosphatase followed by western blotting with alpha-GLI1412-427 revealed the conversion of the upper band of the GLI1130 doublet to the lower one (Figure 7A and D), indicating that the upper band is a phosphoform of GLI1130 (GLI1130P). GLI1100 decreased slightly but did not change size (Figure 7A), and the GLI1FL band became fainter (Figure 7A and not shown), suggesting that it might also be affected although its rarity made further assessment not possible. Consistently, however, the level of exogenous GLI1FL decreased with lambda phosphatase treatment, suggesting that it is phosphorylated and highly unstable in its dephosphorylated form (Supplementary Figure 9G). GLI1FL and GLI1130P, but not of GLI1130, were detected in a phosphoprotein selected pool, confirming their phosphorylated status (Supplementary Figure 9H).
###end p 46
###begin p 47
###xml 55 58 55 58 <sup>130</sup>
###xml 103 107 91 95 <sup>130P</sup>
###xml 162 166 145 149 <sup>130P</sup>
###xml 193 196 176 179 <sup>130</sup>
###xml 198 213 181 196 <xref ref-type="fig" rid="f7">Figure 7B and D</xref>
###xml 231 233 214 216 <sup>FL</sup>
###xml 242 245 225 228 <sup>100</sup>
###xml 327 329 310 312 <sup>FL</sup>
###xml 348 357 331 340 <xref ref-type="fig" rid="f5">Figure 5F</xref>
###xml 359 382 342 365 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 9C</xref>
###xml 497 501 480 484 <sup>130P</sup>
###xml 608 611 591 594 <sup>130</sup>
The kd of p53 in U87 cells increased the levels of GLI1130 approximately6-8-fold at the expense of GLI1130P. Treatment with lambda phosphatase confirmed that GLI1130P is the phosphoform of GLI1130 (Figure 7B and D). Endogenous GLI1FL and GLI1100 were modestly increased by p53 kd, consistent with the increase in exogenous GLI1FL levels by p53 kd (Figure 5F; Supplementary Figure 9C). Similar results were obtained in glioma D54 (p53 wt) cells (not shown). The data raise the possibility that GLI1130P is a latent and stable form, the conversion of which to its unphosphorylated, labile and active form (GLI1130) is antagonised by p53.
###end p 47
###begin p 48
###xml 69 72 69 72 <sup>130</sup>
###xml 81 85 81 85 <sup>130P</sup>
###xml 194 199 194 199 <italic>et al</italic>
###xml 185 205 185 205 <xref ref-type="bibr" rid="b23">Krishnan <italic>et al</italic>, 1997</xref>
###xml 486 490 486 490 <sup>130P</sup>
###xml 513 522 513 522 <xref ref-type="fig" rid="f7">Figure 7D</xref>
###xml 577 580 577 580 <sup>130</sup>
###xml 624 633 624 633 <xref ref-type="fig" rid="f7">Figure 7D</xref>
###xml 651 654 651 654 <sup>130</sup>
###xml 697 701 685 689 <sup>130P</sup>
###xml 818 820 794 796 <sup>FL</sup>
To begin to investigate the mechanisms regulating the balance of GLI1130 and GLI1130P, we focused on phosphatase (PP) activity given the suggested involvement of PP2A in Hh signalling (Krishnan et al, 1997). U87 and U251 cells were treated with low doses of okadaic acid (OA, 10 nM, 16 h) and extracts subjected to western blotting. OA is a serine/threonine protein phosphatase inhibitor with high affinity for PP2A and much lower affinities for PP1 and PP2B. OA increased (50-80%) GLI1130P in control U87 cells (Figure 7D). In p53 kd cells, which have increased levels of GLI1130, OA treatment reversed the 130P/130 ratio (Figure 7D), decreasing GLI1130 by approximately40-50% and augmenting GLI1130P approximately2-fold. Similar results were obtained in U251 cells (not shown). The very low levels of endogenous GLI1FL prevented us from assessing changes after OA treatment (not shown).
###end p 48
###begin p 49
###xml 31 35 31 35 <sup>130P</sup>
###xml 230 239 230 239 <xref ref-type="fig" rid="f7">Figure 7E</xref>
###xml 343 347 343 347 <italic>GLI1</italic>
###xml 352 357 352 357 <italic>PTCH1</italic>
###xml 365 374 365 374 <xref ref-type="fig" rid="f7">Figure 7F</xref>
To correlate the levels of GLI1130P with transcriptional activity, endogenous GLI-dependent reporter function was measured in OA-treated U87 cells. OA reduced reporter levels by 60-70% and abolished the increase induced by shp53 (Figure 7E), paralleling the western blot results. Moreover, OA treatment repressed the endogenous levels of both GLI1 and PTCH1 mRNAs (Figure 7F), confirming the downregulation of the endogenous HH-GLI pathway.
###end p 49
###begin p 50
###xml 152 159 152 159 <italic>shPTCH1</italic>
###xml 163 170 163 170 <italic>shSUFUH</italic>
###xml 247 250 235 238 <sup>130</sup>
###xml 272 276 260 264 <sup>130P</sup>
###xml 309 324 297 312 <xref ref-type="fig" rid="f7">Figure 7B and C</xref>
###xml 369 371 357 359 <sup>FL</sup>
###xml 380 383 368 371 <sup>100</sup>
###xml 433 448 421 436 <xref ref-type="fig" rid="f7">Figure 7B and C</xref>
We also analysed GLI1 isoforms after increasing the strength of HH signalling through kd of the major negative regulators PTCH1 or SUFUH, by RNAi (with shPTCH1 or shSUFUH). Such interference resulted in a approximately2.5-fold upregulation of GLI1130 at the expense of GLI130P mimicking the effect of p53 kd (Figure 7B and C). Enhanced HH signalling also increased GLI1FL and GLI1100 levels by 3-5-fold and 2.5-3-fold, respectively (Figure 7B and C).
###end p 50
###begin p 51
###xml 166 173 166 173 <italic>shSUFUH</italic>
###xml 204 213 204 213 <xref ref-type="fig" rid="f7">Figure 7G</xref>
###xml 271 280 271 280 <xref ref-type="fig" rid="f7">Figure 7G</xref>
###xml 345 350 345 350 <italic>et al</italic>
###xml 337 356 337 356 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 363 366 363 366 <sup>130</sup>
###xml 499 508 499 508 <xref ref-type="fig" rid="f7">Figure 7H</xref>
These results suggested that OA should inhibit the proliferative effects of enhanced HH pathway activation. The increase in BrdU incorporation in U87 cells driven by shSUFUH was reverted by OA treatment (Figure 7G). OA also inhibited untransduced U87 cell proliferation (Figure 7G), which is known to depend on an active HH-GLI pathway (Clement et al, 2007). GLI1130 thus appears to depend on the action of PP2A or a similar enzyme, being positively regulated by HH signalling and inhibited by p53 (Figure 7H).
###end p 51
###begin p 52
###xml 42 46 42 46 <sup>130P</sup>
###xml 136 141 136 141 <italic>et al</italic>
###xml 128 147 128 147 <xref ref-type="bibr" rid="b10">Epstein <italic>et al</italic>, 1996</xref>
###xml 256 275 256 275 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 285 290 285 290 <italic>et al</italic>
###xml 277 296 277 296 <xref ref-type="bibr" rid="b19">Kaesler <italic>et al</italic>, 2000</xref>
###xml 415 420 415 420 <italic>et al</italic>
###xml 409 426 409 426 <xref ref-type="bibr" rid="b47">Sheng <italic>et al</italic>, 2006</xref>
###xml 529 532 529 532 <sup>130</sup>
###xml 665 669 665 669 <sup>130P</sup>
###xml 702 711 702 711 <xref ref-type="fig" rid="f7">Figure 7D</xref>
###xml 786 790 786 790 <sup>130P</sup>
###xml 795 798 795 798 <sup>130</sup>
###xml 854 857 854 857 <sup>130</sup>
###xml 898 907 898 907 <xref ref-type="fig" rid="f7">Figure 7D</xref>
###xml 1035 1038 1035 1038 <sup>130</sup>
The kinases and mechanisms that yield GLI1130P are not known. cAMP-dependent Protein Kinase A (PKA) blocks HH signalling (e.g., Epstein et al, 1996), and its enhancement with forskolin (FK), a selective activator of adenyl cyclase, inhibits GLI1 activity (Ruiz i Altaba, 1999; Kaesler et al, 2000; not shown). PKA promotes GLI1 phosphorylation and its localisation in the cytoplasm, where it can be degraded (Sheng et al, 2006). We therefore tested whether enhanced PKA activity by FK treatment could have the same effect on GLI1130 as inhibiting endogenous PP2A and/or similar phosphatase activity by OA. FK treatment of wt U87 cells yielded similar levels of GLI1130P as control or OA-treated cells (Figure 7D). However, FK treatment of cells expressing shp53 did not reverse the GLI1130P/GLI1130 ratio to the extent that OA treatment did. Rather, GLI1130 was largely eliminated by FK treatment (Figure 7D). The data raise the possibility that the mechanisms by which PKA antagonises GLI1 activity include the degradation of the GLI1130 activator form.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
Here we show that GLI1 is under negative control by p53 in multiple systems, and that GLI1 and p53 form a novel homeostatic inhibitory loop that normally controls precursor and stem cell numbers. We propose that its modification alters the behavior of stem cell lineages leading to increases or decreases in cell numbers, such as those in cancer or aging, respectively.
###end p 54
###begin title 55
The level of GLI1 activity determines brain size and neural stem cell self-renewal
###end title 55
###begin p 56
###xml 206 211 206 211 <italic>et al</italic>
###xml 192 217 192 217 <xref ref-type="bibr" rid="b42">Ruiz i Altaba <italic>et al</italic>, 2007</xref>
###xml 408 413 408 413 <italic>Nanog</italic>
###xml 415 419 415 419 <italic>Klf4</italic>
###xml 424 428 424 428 <italic>Sox2</italic>
###xml 488 493 488 493 <italic>et al</italic>
###xml 480 499 480 499 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 547 575 547 575 <xref ref-type="bibr" rid="b50">Takahashi and Yamanaka, 2006</xref>
###xml 600 601 600 601 <sup>+</sup>
###xml 617 621 617 621 <sup>+dox</sup>
###xml 638 639 638 639 <sup>+</sup>
###xml 697 702 697 702 <italic>et al</italic>
###xml 689 708 689 708 <xref ref-type="bibr" rid="b8">Doetsch <italic>et al</italic>, 1999</xref>
###xml 1114 1119 1114 1119 <italic>et al</italic>
###xml 1106 1125 1106 1125 <xref ref-type="bibr" rid="b32">Nyfeler <italic>et al</italic>, 2005</xref>
###xml 1207 1212 1207 1212 <italic>et al</italic>
###xml 1196 1218 1196 1218 <xref ref-type="bibr" rid="b37">Panchision <italic>et al</italic>, 2001</xref>
###xml 1278 1285 1278 1285 <italic>in vivo</italic>
###xml 1374 1379 1374 1379 <italic>et al</italic>
###xml 1367 1385 1367 1385 <xref ref-type="bibr" rid="b18">Ingram <italic>et al</italic>, 2008</xref>
###xml 1513 1518 1513 1518 <italic>et al</italic>
###xml 1508 1524 1508 1524 <xref ref-type="bibr" rid="b44">Sang <italic>et al</italic>, 2008</xref>
###xml 254 269 <span type="species:ncbi:10090">transgenic mice</span>
GLI1 is the last mediator of HH signals, acts as a nexus to integrate non-HH signals such as RAS, and is an emerging central regulator of stemness and cancer in multiple contexts (reviewed in Ruiz i Altaba et al, 2007). We find that the level of GLI1 in transgenic mice controls precursor and stem cell numbers in multiple brain regions. Consistent with this, GLI1 induces a stemness signature that includes Nanog, Klf4 and Sox2, which parallels that of glioma cancer stem cells (Clement et al, 2007) and includes genes involved in reprogramming (Takahashi and Yamanaka, 2006). As the majority of GFP+ cells in the DT+dox SVZ are not GFAP+, a marker of postnatal semiquiescent stem cells (Doetsch et al, 1999), enhanced GLI1 levels could thus increase the number of actively dividing stem cells. Such increases in brain stem cells and precursors are concomitant with the region-specific modulation of several signalling pathways. Notably, GLI1 upregulates Notch and downregulates critical BMP signalling components, in line with the requirement of Notch-Jagged signalling in neural stem cell self-renewal (Nyfeler et al, 2005), and the pro-differentiative action of BMP signalling on stem cells (Panchision et al, 2001). Moreover, the strong upregulation of Hes1 that we detect in vivo and in cerebellar stem cells is consistent with it being a Notch and Gli target (Ingram et al, 2008; V Wallace, personal communication) and is interesting in view of its recent implication in the prevention of senescence (Sang et al, 2008).
###end p 56
###begin p 57
###xml 140 141 140 141 <sup>+</sup>
###xml 160 164 160 164 <sup>+dox</sup>
###xml 197 201 197 201 <italic>Gli1</italic>
###xml 223 227 223 227 <italic>Gli2</italic>
###xml 232 236 232 236 <italic>Gli3</italic>
###xml 318 323 318 323 <italic>et al</italic>
###xml 313 329 313 329 <xref ref-type="bibr" rid="b38">Park <italic>et al</italic>, 2000</xref>
###xml 428 433 428 433 <italic>et al</italic>
###xml 421 439 421 439 <xref ref-type="bibr" rid="b12">Galvin <italic>et al</italic>, 2008</xref>
###xml 450 454 450 454 <italic>Gli1</italic>
###xml 454 457 454 457 <sup>&#8722;/&#8722;</sup>
###xml 874 879 874 879 <italic>et al</italic>
###xml 867 885 867 885 <xref ref-type="bibr" rid="b22">Kippin <italic>et al</italic>, 2005</xref>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 375 380 <span type="species:ncbi:10090">mouse</span>
###xml 465 470 <span type="species:ncbi:10090">mouse</span>
We suggest a role for endogenous Gli1 in neural stem cells as enhanced GLI1 levels expand the number of clonogenic stem cells, and Prominin1+ stem cells from DT+dox cerebella upregulate endogenous Gli1 while downregulating Gli2 and Gli3 (this work). Moreover, even though it is dispensable for mouse development (Park et al, 2000), acute interference with endogenous Gli1 in mouse hippocampal NS decreases clone numbers (Galvin et al, 2008), and SVZ Gli1-/- mutant mouse NS show a 40% reduction in secondary clonogenicity (M Vukicevic and ARA, personal communication). Gli1 may, therefore, normally contribute to the control of stem cell lineage longevity, acting to balance antagonising p53 function, consistent with the finding that loss of p21, a p53 target, transiently enhances the self-renewal of neural stem cells but then leads to their premature exhaustion (Kippin et al, 2005).
###end p 57
###begin title 58
The balance of antagonistic GLI1 and p53 functions regulates cell numbers
###end title 58
###begin p 59
###xml 190 213 190 213 <xref ref-type="bibr" rid="b16">Harris and Levine, 2005</xref>
###xml 321 330 321 330 <xref ref-type="fig" rid="f7">Figure 7H</xref>
###xml 626 630 626 630 <italic>BMI1</italic>
###xml 685 690 685 690 <italic>et al</italic>
###xml 681 696 681 696 <xref ref-type="bibr" rid="b1">Abe <italic>et al</italic>, 2008</xref>
GLI1 is tightly controlled by multiple mechanisms, and here we show that a novel critical modulator of GLI1 in precursors, stem and tumour cells is p53, a multifunctional tumour suppressor (Harris and Levine, 2005). Our data suggest a model for a novel homeostatic mechanism in which p53 and GLI1 form a regulatory loop (Figure 7H). Here, any inappropriate elevation of GLI1 would induce the DNA damage (replication stress) response, which leads to activation of p53, and elevated p53 would then decrease GLI1 activity. At the same time, however, endogenous GLI1 antagonises endogenous p53, possibly through its regulation of BMI1 or its activation of the p53 inhibitor Hdm2/Mdm2 (Abe et al, 2008; this work).
###end p 59
###begin p 60
###xml 331 336 331 336 <sup>INK4a</sup>
###xml 355 360 355 360 <sup>INK4a</sup>
###xml 407 412 407 412 <italic>et al</italic>
###xml 398 418 398 418 <xref ref-type="bibr" rid="b30">Molofsky <italic>et al</italic>, 2006</xref>
Normal organ-specific regulation of this loop may act to maintain precursors and stem cells in their appropriate numbers to insure life-long persistence and constant organ size, while preventing tumourigenesis. Interestingly, we found that synergistic enhancement of stem cell numbers by GLI1 and p53 kd increased expression of p16INK4a. As increasing p16INK4a levels mark aging neural stem cells (Molofsky et al, 2006), such synergistic action may induce neural stem cell aging, possibly leading to their eventual exhaustion, consistent with the self-renewal deficit in NS lacking Gli1 (see above). The p53-GLI1 regulatory loop might thus not only normally act to maintain size and shape, preventing cancer, but might also act to time aging.
###end p 60
###begin title 61
Control of GLI1 by p53
###end title 61
###begin p 62
###xml 105 107 105 107 <sup>FL</sup>
###xml 113 116 113 116 <sup>130</sup>
###xml 125 128 125 128 <sup>100</sup>
###xml 130 139 130 139 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 231 234 231 234 <sup>130</sup>
###xml 263 265 263 265 <sup>FL</sup>
###xml 416 421 416 421 <italic>et al</italic>
###xml 406 427 406 427 <xref ref-type="bibr" rid="b48">Shimokawa <italic>et al</italic>, 2008</xref>
###xml 517 521 505 509 <italic>GLI1</italic>
###xml 521 523 509 511 <italic>FL</italic>
###xml 521 523 509 511 <sup><italic>FL</italic></sup>
###xml 560 565 548 553 <italic>et al</italic>
###xml 550 571 538 559 <xref ref-type="bibr" rid="b48">Shimokawa <italic>et al</italic>, 2008</xref>
###xml 586 589 574 577 <sup>130</sup>
###xml 625 627 613 615 <sup>FL</sup>
###xml 658 661 646 649 <sup>130</sup>
###xml 671 673 659 661 <sup>FL</sup>
###xml 720 723 708 711 <sup>130</sup>
###xml 773 775 761 763 <sup>FL</sup>
###xml 802 807 790 795 <italic>et al</italic>
###xml 791 813 779 801 <xref ref-type="bibr" rid="b17">Huntzicker <italic>et al</italic>, 2006</xref>
###xml 877 882 865 870 <italic>et al</italic>
###xml 869 888 857 876 <xref ref-type="bibr" rid="b9">Dunaeva <italic>et al</italic>, 2003</xref>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Detailed analyses of exogenous and endogenous human GLI1 reveal that GLI1 exists in different forms: GLI1FL, GLI1130 and GLI1100 (Figure 6A), with the first two likely acting as activators and the last one as a weak repressor. GLI1130 lacks the N-terminus of GLI1FL, and as it is produced from the full-length cDNA, it is distinct from a differential splice form of GLI1 lacking 128aa from the N-terminus (Shimokawa et al, 2008). Indeed, this spliced form is exceedingly rare (approximately19-fold less abundant than GLI1FL on average in cell lines (Shimokawa et al, 2008), whereas GLI1130 is >10-fold more abundant than GLI1FL. The greater abundance of GLI1130 over GLI1FL is consistent with the deduced absence in GLI1130 of two inhibitory sites in the N-terminus of GLI1FL: an N' degron (Huntzicker et al, 2006) and a key binding site for the GLI1 antagonist SUFUH (Dunaeva et al, 2003).
###end p 62
###begin p 63
Our data suggest that p53 acts to inhibit GLI1 function in two ways:
###end p 63
###begin p 64
###xml 54 56 54 56 <sup>FL</sup>
###xml 233 235 233 235 <sup>FL</sup>
###xml 266 269 266 269 <sup>130</sup>
(1) p53 represses the transcriptional activity of GLI1FL by reducing its nuclear localisation and protein levels. This type of regulation is seen with exogenous transfected GLI1 and may be operative with the very rare endogenous GLI1FL protein and possibly with GLI1130.
###end p 64
###begin p 65
###xml 73 76 69 72 <sup>130</sup>
###xml 103 106 99 102 <sup>130</sup>
###xml 161 165 157 161 <sup>130P</sup>
###xml 207 210 203 206 <sup>130</sup>
###xml 283 292 279 288 <xref ref-type="fig" rid="f7">Figure 7I</xref>
###xml 309 311 305 307 <sup>FL</sup>
###xml 365 367 361 363 <sup>FL</sup>
(2) p53 promotes the phosphorylation of the endogenous novel N'Delta GLI1130 isoform. We find that GLI1130 is predominantly found in a phosphorylated state (GLI1130P) and suggest that non-phosphorylated GLI1130 is a labile activator, the abundance of which correlates with activity (Figure 7I). Exogenous GLI1FL also appears to be phosphorylated and endogenous GLI1FL might behave similarly, being subjected also to this second mode of regulation.
###end p 65
###begin p 66
###xml 33 36 33 36 <sup>130</sup>
###xml 157 161 157 161 <sup>130P</sup>
###xml 208 212 208 212 <sup>130P</sup>
###xml 231 234 231 234 <sup>130</sup>
###xml 383 388 377 382 <italic>et al</italic>
###xml 376 394 370 388 <xref ref-type="bibr" rid="b40">Rorick <italic>et al</italic>, 2007</xref>
###xml 458 462 452 456 <sup>130P</sup>
Concerning the regulation of GLI1130, p53 could act, directly or indirectly, to antagonise a protein phosphatase, favouring the inactive and more stable GLI1130P. Treatment with low doses of OA increases GLI1130P and decreases GLI1130. As OA has a higher affinity for PP2A than to PP1 or PP2B, and the B56epsilon subunit of PP2A is required for Gli1 function in frog embryos (Rorick et al, 2007), the phosphatase responsible for the dephosphorylation of GLI1130P may be PP2A.
###end p 66
###begin p 67
###xml 104 108 100 104 <sup>130P</sup>
###xml 191 196 187 192 <italic>et al</italic>
###xml 183 202 179 198 <xref ref-type="bibr" rid="b10">Epstein <italic>et al</italic>, 1996</xref>
###xml 232 251 228 247 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 261 266 257 262 <italic>et al</italic>
###xml 253 272 249 268 <xref ref-type="bibr" rid="b19">Kaesler <italic>et al</italic>, 2000</xref>
###xml 376 379 372 375 <sup>130</sup>
###xml 427 430 423 426 <sup>130</sup>
###xml 558 561 554 557 <sup>130</sup>
###xml 579 583 575 579 <sup>130P</sup>
The mechanism of N'Delta truncation, phosphorylation site(s) and kinases involved in the genesis of GLI1130P remain to be determined. PKA is an important antagonist of HH signalling (Epstein et al, 1996), it inhibits GLI1 activity (Ruiz i Altaba, 1999; Kaesler et al, 2000), and we show that activation of endogenous PKA through FK treatment results in the degradation of GLI1130. We suggest that although the formation of GLI1130 depends on phosphatase activity, its degradation may involve PKA. We also suggest that p53, unlike PKA, acts to antagonise GLI1130 by promoting GLI1130P.
###end p 67
###begin p 68
###xml 152 155 152 155 <sup>130</sup>
###xml 198 203 198 203 <italic>et al</italic>
###xml 194 209 194 209 <xref ref-type="bibr" rid="b26">Lee <italic>et al</italic>, 1997</xref>
As activation of HH signalling (by inhibition of PTCH1 or of SUFUH) also modulates and appears to depend on the level and phosphorylation status of GLI1130, GLI1 is regulated transcriptionally (Lee et al, 1997) and posttranscriptionally by HH signals.
###end p 68
###begin p 69
###xml 40 43 40 43 <sup>130</sup>
###xml 49 52 49 52 <sup>100</sup>
###xml 209 227 205 223 <xref ref-type="bibr" rid="b36">Pan and Wang, 2007</xref>
In contrast to the positive role of GLI1130, GLI1100 might act as an immediate and tonic negative feedback, as it may have repressor activity and resembles the C'Delta repressor form of GLI3, but unlike this (Pan and Wang, 2007), it is not inhibited by Hh signalling.
###end p 69
###begin p 70
###xml 212 217 208 213 <italic>et al</italic>
###xml 205 223 201 219 <xref ref-type="bibr" rid="b45">Sasaki <italic>et al</italic>, 1999</xref>
###xml 276 281 272 277 <italic>et al</italic>
###xml 267 287 263 283 <xref ref-type="bibr" rid="b23">Krishnan <italic>et al</italic>, 1997</xref>
###xml 333 338 329 334 <italic>et al</italic>
###xml 327 344 323 340 <xref ref-type="bibr" rid="b39">Riob&#243; <italic>et al</italic>, 2006</xref>
It is possible that GLI2 and GLI3 share similarities with the novel regulation of GLI1 we describe here, as N'Delta forms are strong transcriptional activators and Gli2 is an early mediator of Hh signals (Sasaki et al, 1999), OA treatment can inhibit Shh signalling (Krishnan et al, 1997) and FK treatment phosphorylates Gli2 (Riobo et al, 2006).
###end p 70
###begin title 71
Imbalance of GLI1 and p53 activities in disease
###end title 71
###begin p 72
###xml 185 209 185 209 <xref ref-type="bibr" rid="b46">Serrano and Blasco, 2007</xref>
###xml 380 385 380 385 <italic>et al</italic>
###xml 372 391 372 391 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 432 457 432 457 <xref ref-type="bibr" rid="b33">Ohgaki and Kleihues, 2007</xref>
###xml 875 880 875 880 <italic>et al</italic>
###xml 955 960 955 960 <italic>et al</italic>
###xml 948 966 948 966 <xref ref-type="bibr" rid="b49">Stecca <italic>et al</italic>, 2007</xref>
###xml 516 521 <span type="species:ncbi:9606">human</span>
###xml 841 846 <span type="species:ncbi:9606">human</span>
###xml 1081 1086 <span type="species:ncbi:9606">human</span>
The homeostatic balance of the GLI1-p53 regulatory loop that we have uncovered appears to be critical. Whereas its imbalance in favour of p53 could affect stem cell lineages and aging (Serrano and Blasco, 2007), imbalance in favour of GLI1 appears to be predominant in cancer and cancer stem cells. For example, glioma cancer stem cells require sustained HH-GLI function (Clement et al, 2007) and gliomas frequently lack p53 (e.g., Ohgaki and Kleihues, 2007). We suggest that loss of p53, which is a common event in human cancers, unleashes the normally restricted proliferative and self-renewing activities of GLI1, leading to an expansion of cancer stem cells and derived progenitors. Tumor suppressors may thus normally act to regulate stem cell lineages. In addition to p53 control, the positive regulation of GLI1 activity by the major human oncogenes (RAS, AKT; Stecca et al, 2007), and its negative regulation by the tumour suppressor PTEN (Stecca et al, 2007), highlights the exquisite regulation of GLI1 activity and provides a rationale for its widespread involvement in human cancer.
###end p 72
###begin title 73
Materials and methods
###end title 73
###begin p 74
###xml 42 60 42 60 <xref ref-type="supplementary-material" rid="S1">Supplementary data</xref>
A full account of all methods is given in Supplementary data.
###end p 74
###begin title 75
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice, neurospheres and cell lines
###end title 75
###begin p 76
###xml 22 26 22 26 <italic>GLI1</italic>
###xml 131 153 131 153 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 191 221 191 221 <xref ref-type="bibr" rid="b35">Palma and Ruiz i Altaba (2004)</xref>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
Doxycycline-regulated GLI1 transgenic (GFP<-tetO->GLI1) mice were crossed with Nestin->rtTA-IRES-LacZ mice to obtain bigenic mice (Supplementary Figure 1). NS were prepared from brains as in Palma and Ruiz i Altaba (2004), transduced with lentivectors and analysed 4-5 days afterwards.
###end p 76
###begin title 77
Plasmids, lentiviral vectors and RNA interference
###end title 77
###begin p 78
###xml 182 201 170 189 <xref ref-type="bibr" rid="b41">Ruiz i Altaba, 1999</xref>
###xml 234 240 222 228 <sup>Thr280</sup>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
Transfections were at equimolar amounts unless otherwise specified with pCS2-Myc-tagged human GLI1, GLI1DeltaN', GLI2DeltaN', GLI3, GLI3R (GLI3C'DeltaClaI), frog Gli1, frog NLSGli1 (Ruiz i Altaba, 1999), wt human p53, human dnp53 (p53Thr280), pCMV-EGFP or pCMV-LacZ.
###end p 78
###begin p 79
###xml 48 53 48 53 <italic>et al</italic>
###xml 40 59 40 59 <xref ref-type="bibr" rid="b3">Clement <italic>et al</italic>, 2007</xref>
###xml 367 372 367 372 <italic>et al</italic>
###xml 359 379 359 379 <xref ref-type="bibr" rid="b43">Sanchez <italic>et al</italic> (2004)</xref>
###xml 155 160 <span type="species:ncbi:9606">human</span>
###xml 193 198 <span type="species:ncbi:10090">mouse</span>
###xml 309 314 <span type="species:ncbi:9606">human</span>
Lentiviral vectors were pLV-CTH-shSMOH (Clement et al, 2007); pLV-CTH-shPTCH1 with targeting sequence 5'-GCACTATGCTCCTTTCCTC-3'; pLV-WPXL-shp53 (targeting human p53); pLV-Sico-shp53 (targeting mouse p53 Addgene); pLV-KO.1-puro-shSHFUH (Sigma); and pLV-GLI1 was in pLV-Lox-CW or pLV-TWEEN. siRNA sequences for human GLI1 and control siRNA were as described in Sanchez et al (2004).
###end p 79
###begin title 80
###xml 53 54 53 54 <sup>+</sup>
Luciferase reporter assays and isolation of Prominin1+ cells
###end title 80
###begin p 81
###xml 72 77 72 77 <italic>et al</italic>
###xml 65 83 65 83 <xref ref-type="bibr" rid="b45">Sasaki <italic>et al</italic> (1999</xref>
###xml 160 164 160 164 <sup>+dox</sup>
###xml 171 175 171 175 <sup>&#8722;dox</sup>
GLI-binding site luciferase reporter assays were as described in Sasaki et al (1999). Cortical and SVZ NS were transfected by nucleofection (Amaxa). Cells of DT+dox and DT-dox brains were dissociated, labelled with Prominin1-microbeads and purified in a magnetic-activated cell-sorting column (Miltenyi Biotec).
###end p 81
###begin title 82
Intracranial xenografts and RNA microinjection
###end title 82
###begin p 83
###xml 55 56 55 56 <sup>5</sup>
###xml 246 251 246 251 <italic>et al</italic>
###xml 238 257 238 257 <xref ref-type="bibr" rid="b4">Dahmane <italic>et al</italic> (1997</xref>
###xml 259 263 259 263 <xref ref-type="bibr" rid="b6">2001</xref>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Lentivector-transduced U87 human glioblastoma cells (105) were grafted using a stereotaxic apparatus (L2,P1,D2 relative to Bregma). Synthetic RNA and MO (Genetools) microinjection into four-cell frog embryos was performed as described in Dahmane et al (1997, 2001).
###end p 83
###begin title 84
Immunohistochemistry, in situ hybridisation and PCR
###end title 84
###begin p 85
###xml 79 86 79 86 <italic>In situ</italic>
###xml 166 171 166 171 <italic>et al</italic>
###xml 158 177 158 177 <xref ref-type="bibr" rid="b4">Dahmane <italic>et al</italic> (1997</xref>
###xml 179 183 179 183 <xref ref-type="bibr" rid="b6">2001</xref>
Cryostat sections were Xgal stained or immunostained with antibodies as noted. In situ hybridisation with digoxygenin-labelled RNA probes was as described in Dahmane et al (1997, 2001). Quantitative rtPCR with cDNA was carried out at 60degreesC using iQTm SYBR green mix (Bio-Rad).
###end p 85
###begin title 86
Western blotting
###end title 86
###begin p 87
GLI1 protein was detected in westerns with anti-myc tag or anti-GLI1 antibodies and ECL chemiluminescence (Amersham), or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) for endogenous GLI1.
###end p 87
###begin title 88
Supplementary Material
###end title 88
###begin p 89
Supplementary Figure 1
###end p 89
###begin p 90
Supplementary Figure 2
###end p 90
###begin p 91
Supplementary Figure 3
###end p 91
###begin p 92
Supplementary Figure 4
###end p 92
###begin p 93
Supplementary Figure 5
###end p 93
###begin p 94
Supplementary Figure 6
###end p 94
###begin p 95
Supplementary Figure 7
###end p 95
###begin p 96
Supplementary Figure 8
###end p 96
###begin p 97
Supplementary Figure 9
###end p 97
###begin p 98
Supplementary data
###end p 98
###begin p 99
We are grateful to N Dahmane, T Halazonetis and all Ruiz i Altaba laboratory members for discussion; M Vukicevic for p53 sequencing data; C Mas for GLI1 lentivectors; G Zacchetti for technical help; T Halazonetis for antibodies; J Massague for p53; M Serrano for protocols; D Trono and P Salmon for lentivectors; P Vize for dnp53; N Dahmane for U251 and Daoy cells, and DD Bigner for D54 cells. Grant support was from the NIH-NINDS, SNF, Oncosuisse, and the Louis-Jeantet Foundation to ARA.
###end p 99
###begin article-title 100
Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.
###end article-title 100
###begin article-title 101
Gli2 functions in FGF signaling during antero-posterior patterning.
###end article-title 101
###begin article-title 102
###xml 34 39 <span type="species:ncbi:9606">human</span>
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.
###end article-title 102
###begin article-title 103
Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours.
###end article-title 103
###begin article-title 104
Sonic hedgehog regulates the growth and patterning of the cerebellum.
###end article-title 104
###begin article-title 105
The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis.
###end article-title 105
###begin article-title 106
###xml 129 137 129 137 <italic>in vitro</italic>
###xml 142 149 142 149 <italic>in vivo</italic>
Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo.
###end article-title 106
###begin article-title 107
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.
###end article-title 107
###begin article-title 108
Characterization of the physical interaction of Gli proteins with SUFU proteins.
###end article-title 108
###begin article-title 109
Antagonizing cAMP-dependent protein kinase A in the dorsal CNS activates a conserved Sonic hedgehog signaling pathway.
###end article-title 109
###begin article-title 110
Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis.
###end article-title 110
###begin article-title 111
Gli1 induces G2/M arrest and apoptosis in hippocampal but not tumor-derived neural stem cells.
###end article-title 111
###begin article-title 112
Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.
###end article-title 112
###begin article-title 113
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Altered neural cell fates and medulloblastoma in mouse patched mutants.
###end article-title 113
###begin article-title 114
###xml 67 72 <span type="species:ncbi:9606">human</span>
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
###end article-title 114
###begin article-title 115
The p53 pathway: positive and negative feedback loops.
###end article-title 115
###begin article-title 116
Dual degradation signals control Gli protein stability and tumor formation.
###end article-title 116
###begin article-title 117
Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling.
###end article-title 117
###begin article-title 118
Transcriptional activity of GLI1 is negatively regulated by protein kinase A.
###end article-title 118
###begin article-title 119
###xml 100 105 <span type="species:ncbi:9606">human</span>
Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.
###end article-title 119
###begin article-title 120
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
###end article-title 120
###begin article-title 121
p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity.
###end article-title 121
###begin article-title 122
Mediation of Sonic hedgehog-induced expression of COUP-TFII by a protein phosphatase.
###end article-title 122
###begin article-title 123
###xml 63 71 63 71 <italic>in vitro</italic>
###xml 76 83 76 83 <italic>in vivo</italic>
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo.
###end article-title 123
###begin article-title 124
Isolation of neural stem cells from the postnatal cerebellum.
###end article-title 124
###begin article-title 125
Gli1 is a target of Sonic hedgehog that induces ventral neural tube development.
###end article-title 125
###begin article-title 126
###xml 124 129 <span type="species:ncbi:9606">human</span>
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.
###end article-title 126
###begin article-title 127
alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway.
###end article-title 127
###begin article-title 128
p53 suppresses the self-renewal of adult neural stem cells.
###end article-title 128
###begin article-title 129
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing.
###end article-title 129
###begin article-title 130
Cooperative requirement of the Gli proteins in neurogenesis.
###end article-title 130
###begin article-title 131
Jagged1 signals in the postnatal subventricular zone are required for neural stem cell self-renewal.
###end article-title 131
###begin article-title 132
Genetic pathways to primary and secondary glioblastoma.
###end article-title 132
###begin article-title 133
Sonic hedgehog controls stem cell behavior in the postnatal and adult brain.
###end article-title 133
###begin article-title 134
Hedgehog-GLI signaling regulates the behavior of cells with stem cell properties in the developing neocortex.
###end article-title 134
###begin article-title 135
A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome.
###end article-title 135
###begin article-title 136
Sequential actions of BMP receptors control neural precursor cell production and fate.
###end article-title 136
###begin article-title 137
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation.
###end article-title 137
###begin article-title 138
Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling.
###end article-title 138
###begin article-title 139
PP2A: B56epsilon is required for eye induction and eye field separation.
###end article-title 139
###begin article-title 140
Gli proteins encode context-dependent positive and negative functions: implications for development and disease.
###end article-title 140
###begin article-title 141
The Gli code: an information nexus regulating cell fate, stemness and cancer.
###end article-title 141
###begin article-title 142
Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.
###end article-title 142
###begin article-title 143
Control of the reversibility of cellular quiescence by the transcriptional repressor HES1.
###end article-title 143
###begin article-title 144
Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling.
###end article-title 144
###begin article-title 145
Cancer and ageing: convergent and divergent mechanisms.
###end article-title 145
###begin article-title 146
Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal.
###end article-title 146
###begin article-title 147
###xml 6 11 <span type="species:ncbi:9606">human</span>
Novel human glioma-associated oncogene 1 (Gli1) splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal.
###end article-title 147
###begin article-title 148
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.
###end article-title 148
###begin article-title 149
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.
###end article-title 149
###begin article-title 150
###xml 52 59 <span type="species:ncbi:8355">Xenopus</span>
p53 activity is essential for normal development in Xenopus.
###end article-title 150
###begin article-title 151
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.
###end article-title 151
###begin article-title 152
GLI activates transcription through a herpes simplex viral protein 16-like activation domain.
###end article-title 152
###begin p 153
###xml 66 67 66 67 <bold>A</bold>
###xml 68 69 68 69 <bold>D</bold>
###xml 73 77 73 77 <sup>+dox</sup>
###xml 168 172 168 172 <sup>&#8722;dox</sup>
###xml 283 300 283 300 <italic>Nestin-&gt;rtTA-LacZ</italic>
###xml 320 342 320 342 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 1</xref>
###xml 346 347 346 347 <bold>E</bold>
###xml 348 349 348 349 <bold>H</bold>
###xml 465 469 465 469 <italic>LacZ</italic>
###xml 521 525 521 525 <italic>GLI1</italic>
###xml 530 535 530 535 <italic>Ptch1</italic>
###xml 567 571 567 571 <sup>&#8722;dox</sup>
###xml 578 582 578 582 <sup>+dox</sup>
###xml 607 608 607 608 <bold>I</bold>
###xml 609 610 609 610 <bold>K</bold>
###xml 620 621 616 617 <sup>&#8722;</sup>
###xml 628 629 624 625 <sup>+</sup>
###xml 633 634 629 630 <sup>+</sup>
###xml 799 800 795 796 <sup>+</sup>
###xml 826 827 822 823 <sup>+</sup>
###xml 946 947 942 943 <bold>L</bold>
###xml 948 949 944 945 <bold>P</bold>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Enhanced GLI1 activity induces a larger brain with hyperplasias. (A-D) DT+dox bigenic mice with strong phenotypes are perinatal lethal exhibiting a larger brain than DT-dox siblings, seen dorsally (A, B) or in sagittal sections after Xgal staining highlighting the expression of the Nestin->rtTA-LacZ driver (C, D) (see Supplementary Figure 1). (E-H) Phenotypes detected in cross section in the thalamus (Thal; E, F), cerebellum (Cb) and medulla (Md; G, H) showing LacZ (Xgal) labelling (E-H), BrdU incorporation (G, H), GLI1 and Ptch1 (F) or GFP (H) expression in DT-dox and DT+dox siblings as indicated. (I-K) HP1gamma-/Nestin+/GFP+ precursors from the ventricle (v) invade the parenchyma through the cortical plate and expand near the pial (p) surface in the cingulate cortex (I, J). Invading GFP+ cells associate with CD34+ endothelial cells in vessels as seen in a Z-stack confocal reconstruction (K) and a confocal image detail (K inset). (L-P) Phenotypic analyses in cross sections of subventricular zone of the lateral ventricle (SVZ) (L) and thalamus (M-P) for the markers indicated. Myc-GLI1 was mostly cytoplasmic and Prox1 nuclear (O inset). L shows a confocal image. Tissue is counterstained with eosin (e.g., C, D, M) and nuclei with DAPI (e.g., I, L). Hip, hippocampus; Sc, spinal cord; Tct, tectum; vz, ventricular zone; Scale bar=1.5 mm (A, B), 1 mm (C, D), 0.5 mm (E-H), 100 mum (O inset, J, P), 200 mum (I), 70 mum (L; H inset), 14 mum (K), 10 mum (K inset), 0.6 mm (M, N, O), 150 mum (M inset).
###end p 153
###begin p 154
###xml 72 73 72 73 <bold>A</bold>
###xml 278 283 278 283 <italic>Gapdh</italic>
###xml 285 294 285 291 <italic>&#946;actin</italic>
###xml 299 307 296 300 <italic>EFI&#945;</italic>
###xml 327 331 320 324 <sup>+dox</sup>
###xml 334 338 327 331 <sup>&#8722;dox</sup>
###xml 357 379 350 372 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5</xref>
###xml 382 383 375 376 <bold>B</bold>
###xml 429 433 422 426 <sup>+dox</sup>
###xml 439 440 432 433 <bold>C</bold>
###xml 441 442 434 435 <bold>E</bold>
###xml 500 501 493 494 <sup>+</sup>
###xml 584 585 577 578 <bold>F</bold>
###xml 600 604 593 597 <italic>GLI1</italic>
###xml 628 632 621 625 <italic>GLI1</italic>
###xml 718 719 711 712 <bold>G</bold>
###xml 720 721 713 714 <bold>I</bold>
###xml 842 843 835 836 <sup>+</sup>
###xml 871 894 864 887 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 6B</xref>
###xml 961 962 954 955 <italic>P</italic>
Gene expression and cellular behaviour in neurospheres and stem cells. (A) RT-qPCR analyses of P0 dissected tissues from cortex (Ctx), thalamus (Thal) or cerebellum (Cb). qPCR values in all panels reflect ct values after normalisation with the geometrical mean of the values of Gapdh, betaactin and EFIalpha and shown as the DT+dox/DT-dox value ratios. See Supplementary Figure 5. (B) Phase contrast and fluorescence images of DT+dox NS. (C-E). Histograms of the number of neurospheres (C, D) or BrdU+ cells (E) as indicated. Primary spheres were quantified per 250 000 brain cells. (F) The level of GLI1 determines NS numbers. GLI1 expression values and secondary sphere number were determined for the same samples. (G-I) Quantification of the number (G), clonogenicity after MACS (H) and gene expression analyses (I) by RT-qPCR of Prominin1+ cerebellar stem cells (see Supplementary Figure 6B). Here and in all figures asterisks denote significative changes (P<0.05) and error bars are s.e.m. Scale bar=80 mum (B).
###end p 154
###begin p 155
###xml 98 99 98 99 <bold>A</bold>
###xml 100 101 100 101 <bold>F</bold>
###xml 418 419 418 419 <bold>G</bold>
###xml 547 548 547 548 <bold>H</bold>
###xml 612 613 612 613 <italic>n</italic>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 437 442 <span type="species:ncbi:10090">mouse</span>
Synergistic control of neural stem cell self-renewal and xenograft growth by GLI1 and kd of p53. (A-F) Quantification of the behaviour of E17.5 NS from cortex (Ctx) or thalamus (Thal) (A-C) or of first week postnatal SVZ NS (D-F) testing for clonogenicity (A, D), proliferation (B, E) and apoptosis (C, F). Cells were derived from DT mice and treated as indicated or were wt NS transduced with lentivectors as shown. (G) Dorsal views of mouse brains uninjected or injected with transduced U87 cells as indicated. Tumour contours (t) are denoted. (H) Quantification of tumour weights versus time after injection; n=5 for each condition. c=control lentivector. Scale bar=0.4 mm (G).
###end p 155
###begin p 156
###xml 69 70 69 70 <bold>A</bold>
###xml 71 72 71 72 <bold>C</bold>
###xml 249 250 249 250 <bold>D</bold>
###xml 336 337 336 337 <bold>E</bold>
###xml 672 673 672 673 <bold>F</bold>
###xml 674 675 674 675 <bold>H</bold>
Mutual requirements of p53 and GLI1 in proliferation and apoptosis. (A-C) Histograms of the changes in cell proliferation (A, B) or apoptosis (C) after altering SMOH, GLI1 or p53 levels by lentiviral transduction or siRNA lipofection in U87 cells. (D) Compensatory effects in cell proliferation in U251 and Daoy cells by GLI1 and p53. (E) Left: Rescue of the anti-proliferative effect of p53 induction by oxaliplatin (48 h) by transduced GLI1 in U87 cells. Comparisons are with untreated (0) control (c) except where noted. Right: Western blot of the levels of p53 and phospho-serine15 p53 induced by oxaliplatin with or without exogenous GLI1. Hsp90 is used as control. (F-H) Quantification (F) and whole-mount side views (G, H) of Xgal-stained stage 32 tadpoles facing the centre of each panel with epidermal hyperplasias (arrows; top rows, G, H) or the normal distribution of cells in the epidermis (bottom rows, G, H) as indicated. Scale bar=0.6 mm (G, H).
###end p 156
###begin p 157
###xml 28 29 28 29 <bold>A</bold>
###xml 30 31 30 31 <bold>C</bold>
###xml 120 122 120 122 <sup>FL</sup>
###xml 335 336 335 336 <bold>D</bold>
###xml 338 339 338 339 <bold>E</bold>
###xml 433 434 433 434 <bold>F</bold>
###xml 435 436 435 436 <bold>H</bold>
###xml 508 512 508 512 <sup>+dox</sup>
###xml 624 629 624 629 <italic>Ptch1</italic>
###xml 629 632 629 632 <sup>+/&#8722;</sup>
###xml 632 636 632 636 <italic>;p53</italic>
###xml 636 639 636 639 <sup>&#8722;/&#8722;</sup>
Regulation of GLI1 by p53. (A-C) Quantification of GLI-dependent luciferase reporter assays (A-C) and inhibition of GLI1FL by p53 (C). Luciferase units are GLI reporter firefly/renilla control ratios with the level induced by GLI1 equated to 100%. p53 was used at 1/0.25, 1/0.5, 1/1 maintaining equal amounts of GLI1 (triangle in C). (D, E) Representative images (D) and quantification of GLI nuclear localisation in U87 cells (E). (F-H) Western blots showing the expression of transgenic GLI1 in thalamic DT+dox NS (F), endogenous Gli1 in postnatal SVZ NS (G) and endogenous Gli1 in P10 and adult cerebella as well as in a Ptch1+/-;p53-/- medulloblastoma (MB; H). Transduction with shp53 lentivectors leads to an increase in the abundance of transgenic GLI1 (F) and endogenous Gli1 (G). p53 and Hsp90 are used as controls. Scale bar=15 mum (D).
###end p 157
###begin p 158
###xml 65 66 65 66 <bold>A</bold>
###xml 178 180 178 180 <sup>FL</sup>
###xml 200 201 200 201 <bold>B</bold>
###xml 231 234 231 234 <sup>130</sup>
###xml 243 246 243 246 <sup>100</sup>
###xml 254 256 254 256 <sup>FL</sup>
###xml 327 328 327 328 <bold>C</bold>
###xml 437 439 437 439 <sup>FL</sup>
###xml 448 451 448 451 <sup>130</sup>
###xml 549 552 549 552 <sup>100</sup>
###xml 555 556 555 556 <bold>D</bold>
###xml 652 653 652 653 <bold>E</bold>
###xml 870 871 870 871 <bold>F</bold>
###xml 945 946 945 946 <bold>G</bold>
###xml 980 983 980 983 <sup>130</sup>
###xml 342 347 <span type="species:ncbi:9606">human</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
GLI1 protein isoforms and endogenous repression of p53 by GLI1. (A) Transfected myc-GLI1 isoforms detected as indicated in samples treated with cycloheximide (CHX) as shown. GLI1FL migrates >160 KD. (B) Deduced relationship of GLI1130 and GLI1100 to GLI1FL, and location of Ab epitopes and of the transactivating (TA) domain. (C) Analyses of human GLI1 protein in transgenic P0 mice as indicated. All three antibodies used recognise GLI1FL and GLI1130, but only those to the domain immediately C-terminal to the zinc fingers (ZF in B) recognise GLI1100. (D) Analysis of GLI1 isoforms in human cell lines and in a GBM stem cell culture (gliomasphere). (E) GLI1 kd with a specific siRNA for 8 h, but not a control siRNA, depletes all three isoforms in U87 cells, while enhancing total and phospho-serine15 p53 (p53-P) levels. Non-specific bands are denoted by asterisks. (F) Levels of Mdm2 in the blot shown in panel C middle for GLI1 and Hsp90. (G) Comparison of the levels of GLI1130, p53, phospho-serine15 p53 and HSP90 in two gliomaspheres that proliferate at different rates.
###end p 158
###begin p 159
###xml 62 65 62 65 <sup>130</sup>
###xml 93 94 93 94 <bold>A</bold>
###xml 228 229 218 219 <bold>B</bold>
###xml 231 232 221 222 <bold>C</bold>
###xml 286 289 274 277 <sup>130</sup>
###xml 342 345 330 333 <sup>130</sup>
###xml 350 354 338 342 <sup>130P</sup>
###xml 397 400 385 388 <sup>130</sup>
###xml 419 420 407 408 <bold>D</bold>
###xml 501 504 489 492 <sup>130</sup>
###xml 600 601 583 584 <bold>E</bold>
###xml 737 738 720 721 <bold>F</bold>
###xml 827 831 810 814 <italic>GLI1</italic>
###xml 838 840 821 823 <sup>&#8722;4</sup>
###xml 846 851 829 834 <italic>PTCH1</italic>
###xml 858 860 841 843 <sup>&#8722;3</sup>
###xml 864 865 847 848 <bold>G</bold>
###xml 979 980 962 963 <bold>H</bold>
###xml 1015 1016 998 999 <bold>I</bold>
###xml 1045 1048 1028 1031 <sup>130</sup>
Regulation of GLI1 isoforms and phosphorylation status of GLI1130 by p53 and HH signalling. (A) Effects of lambda phosphatase treatment (+lambdaPPase) or of shp53, shPTCH1 or shSUFUH. Endogenous p53 and SUFUH levels are shown. (B, C) Enlargements of the +/-130 KD area in (A). The %GLI1130 calculated by densitometry in relation to total GLI1130+GLI1130P values is green. The fold increase in GLI1130/control is blue. (D) Effects of shp53, and of okadaic acid (OA) and forskolin (FK) for 16 h, on GLI1130 isoforms in U87 cells. lambdaPPase treatments and p53 and p53-P levels are shown as controls. (E) Quantification of endogenous GLI-luciferase assays in control U87 cells and after 16 h OA treatment in wt or shp53-expressing cells. (F) RT-qPCR of control and OA-treated U87 cells after 12 h showing decreased expression of GLI1 ( x 10-4) and PTCH1 ( x 10-3). (G) Quantification of BrdU incorporation in control and shSUFUH-transduced U87 cells treated or untreated with OA. (H) GLI1-p53 inhibitory loop model. (I) Proposed regulation of GLI1130 by PP2A or a similar enzyme, HH and p53 activities.
###end p 159

